CA2476008C - Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them - Google Patents

Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them Download PDF

Info

Publication number
CA2476008C
CA2476008C CA2476008A CA2476008A CA2476008C CA 2476008 C CA2476008 C CA 2476008C CA 2476008 A CA2476008 A CA 2476008A CA 2476008 A CA2476008 A CA 2476008A CA 2476008 C CA2476008 C CA 2476008C
Authority
CA
Canada
Prior art keywords
group
amino
morpholin
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2476008A
Other languages
French (fr)
Other versions
CA2476008A1 (en
Inventor
Frank Himmelsbach
Birgit Jung
Flavio Solca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10214412A external-priority patent/DE10214412A1/en
Priority claimed from DE2002131711 external-priority patent/DE10231711A1/en
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CA2476008A1 publication Critical patent/CA2476008A1/en
Application granted granted Critical
Publication of CA2476008C publication Critical patent/CA2476008C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Abstract

The present invention relates to bicyclic heterocyclic groups of general formula (see formula I) wherein R a, R b, R c, R d and X are defined as in claim 1, the tautomers, the stereoisomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases, as well as benign prostate hyperplasia (BPH), diseases of the lungs and respiratory tract, and the preparation thereof.

Description

Boehringer Ingelheim Pharma KG 1 Case 111317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text 80371 fftlatest Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them The present invention relates to bicyclic heterocyclic groups of general formula R-, N,Rb 0,R
X

N Rd (I), the tautomers, the stereoisomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases, as well as benign prostate hyperplasia (BPH), diseases of the lungs and respiratory tract, and the preparation thereof.

In the above general formula I

Ra denotes a hydrogen atom or a C1-4-alkyl group, Rb denotes a phenyl or 1-phenylethyl group, wherein the phenyl nucleus is substituted in each case by the groups R1 to R3, while R1 and R2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom, a C1 -alkyl, hydroxy, Ci_4-alkoxy, C2_3-alkenyl or C2_3-alkynyl group, an aryl, aryloxy, arylmethyl or arylmethoxy group, Boehringer Ingelheim Pharma KG 2 Case 111317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text a heteroaryl, heteroaryloxy, heteroarylmethyl or heteroarylmethoxy group, a methyl or methoxy group substituted by 1 to 3 fluorine atoms or a cyano, nitro or amino group, and R3 denotes a hydrogen, fluorine, chlorine or bromine atom or a methyl or trifluoromethyl group, Rc denotes a cyclobutyl, cyclopentyl or cyclohexyl group which is substituted in each case by a group R4-N-R5, while R4 denotes a hydrogen atom or a C1.3-alkyl group and R5 denotes a hydrogen atom or a C1-3-alkyl group, an aminocarbonyl-Cl-3-alkyl, C1.3-alkylaminocarbonyl-C1-3-alkyl, di-(C1_3-alkyl)aminocarbonyl-C1_3-alkyl, pyrrolidin-1-ylcarbonyl-C1_3-alkyl, piperidin-1-ylcarbonyl-C1.3-alkyl, homopiperidin-1-ylcarbonyl-C1-3-alkyl, morpholin-4-ylcarbonyl-C1-3-alkyl, homomorpholin-4-ylcarbonyl-C1_3-alkyl, piperazin-1-ylcarbonyl-C1-3-alkyl, 4-C1.3-alkyl-piperazin-1-ylcarbonyl-C1_3-alkyl, homopiperazin-l-ylcarbonyl-C1.3-alkyl or a 4-C1_3-alkyl-homopiperazin-1-ylcarbonyl-C1_3-alkyl group, a hydroxy-C2_4-alkyl, C1_3-alkyloxy-C2_4-alkyl, C1.4-alkyloxy-carbonylamino-C2_4-alkyl, amino-C2.4-alkyl, C1.3-alkylamino-C2_4-alkyl, di-(C1-3-alkyl)amino-C2_4-alkyl, C1.3-alkylcarbonylamino-C2_4-alkyl, aminocarbonylamino-C2.4-alkyl, C1_3-alkylaminocarbonylamino-C2_4-alkyl, di-(C1-3-alkyl)amino-carbonylamino-C2-4-alkyl, pyrrolidin-1-ylcarbonylamino-C2.4-alkyl, piperidin-1-ylcarbonylamino-C2.4-alkyl, morpholin-4-ylcarbonylamino-C2.4-alkyl, C1.3-alkylsulphonyl-C2-4-alkyl or Boehringer Ingelheim Pharma KG 3 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text a C1_3-alkylsulphonylamino-C2-4-alkyl group, a (2-oxo-pyrrolidin-1-yl)-C2_4-alkyl, (2-oxopiperidin-1-yl)-C2-4-alkyl, (3-oxo-morpholin-4-yl)-C2.4-alkyl, (2-oxo-imidazolidin-1-yl)-C2-a-alkyl, (2-oxo-3-C1_3-alkyl-imidazolidin-1-yl)-C2-4-alkyl, (2-oxo-hexahydropyrimidin-1-yl)-C2-4-alkyl or a (2-oxo-3-C1.3-alkyl-hexahydropyrimidin-1-yl)-C2-4-alkyl group, a C1.4-alkylsulphonyl, chloro-C1_4-alkylsulphonyl, bromo-C1_4-alkylsulphonyl, amino-C1 -alkylsulphonyl, C1.3-alkylamino-C1.4-alkylsulphonyl, di-(C1.3-alkyl)amino-C1-4-alkylsulphonyl, (pyrrolidin-1-yl)-C1.4-alkylsulphonyl, (piperidin-1-yl)-C1-4-alkylsulphonyl, (homopiperidin-1-yl)-C1.4-alkylsulphonyl, (morpholin-4-yi)-C1_4-alkyl-sulphonyl, (homomorpholin-4-yi)-C1-4-alkylsulphonyl, (piperazin-1-yl)-C1-4-alkylsulphonyl, (4-C1_3-alkyl-piperazin-1-yl)-C1-4-alkylsulphonyl, (homopiperazin-1-yl)-C1-4-alkylsulphonyl or a (4-C1-3-alkyl-homopiperazin-1-yl)-C1-4-alkylsulphonyl group, a C1_4-alkyloxycarbonyl group, a formyl, C1-4-alkyl-carbonyl, C1.3-alkyloxy-Cl.4-alkyl-carbonyl, tetra hydrofuranylcarbonyl, tetrahydropyranylcarbonyl, amino-C1_4-alkyl-carbonyl, C1.3-alkylamino-C1_4-alkyl-carbonyl, di-(C1-3-alkyl)amino-C1_4-alkyl-carbonyl, pyrrolidin-1-yl-C1 -alkyl-carbonyl, piperidin-1-yl-C1-4-alkyl-carbonyl, (homopiperidin-1-yl)-C1-4-alkyl-carbonyl, morpholin-4-yI-C1_4-alkyl-carbonyl, (homomorpholin-4-yl)-C1.4-alkyl-carbonyl, (piperazin-1-yl)-C1-4-alkyl-carbonyl, (4-C1.3-alkyl-piperazin-1-yl)-C1_4-alkyl-carbonyl, (homopiperazin-1-yl)-C1-4-alkyl-carbonyl, (4-C1_3-alkyl-homopiperazin-1-yl)-C1_4-alkyl-carbonyl or a C1_3-alkylsulphonyl-C1_4-alkyl-carbonyl group, a cyano, aminocarbonyl, C1-3-alkyl-aminocarbonyl, di-(C1.3-alkyl)amino-carbonyl, (C1.3-alkyloxy-C2-a-alkyl)aminocarbonyl, N-(C1_3-alkyl)-N-(C1_3-alkyloxy-C2_4-alkyl)aminocarbonyl, arylaminocarbonyl, pyrrolidin-1-Boehringer Ingelheim Pharma KG 4 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text ylcarbonyl, piperidin-1-ylcarbonyl, homopiperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, homomorpholin-4-ylcarbonyl, 2-oxa-5-aza-bicyclo[2.2.1 ]hept-5-ylcarbonyl, 3-oxa-8-aza-bicyclo[3.2.1 ]oct-8-ylcarbonyl, 8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-ylcarbonyl, piperazin-1-ylcarbonyl, 4-C1_3-alkyl-piperazin-1-ylcarbonyl, homopiperazin-1-ylcarbonyl, 4-C1_3-alkyl-homopiperazin-1-ylcarbonyl, aminosulphonyl, C1_3-alkyl-aminosulphonyl, di-(C1.3-alkyl)amino-sulphonyl, pyrrolidin-1-yl-sulphonyl, piperidin-l-ylsulphonyl, homopiperidin-1-ylsulphonyl, morpholin-4-ylsulphonyl, homomorpholin-4-ylsulphonyl, piperazin-1-ylsuiphonyl, 4-C1_3-alkyl-piperazin-1-ylsulphonyl, homopiperazin-1-ylsulphonyl or a 4-C1_3-alkyl-homopiperazin-1-ylsulphonyl group, a cyclobutyl, cyclopentyl or cyclohexyl group which is substituted in each case by a group R6, where R6 denotes a 2-oxo-pyrrolidin-1-yi, 2-oxopiperidin-1-yl, 3-oxo-morpholin-4-yl, 2-oxo-imidazolidin-1-yl, 2-oxo-3-C1-3-alkyl-imidazolidin-1-yl, 2-oxo-hexahydropyrimidin-1 -yl or a 2-oxo-3-C1_3-alkyl-hexahydropyrimidin-1-yl group, an azetidin-3-yl group which is substituted in the 1 position by the group R5, while R5 is as hereinbefore defined, a pyrrolidin-3-yl group which is substituted in the 1 position by the group R5, while R5 is as hereinbefore defined, a piperidin-3-yl group which is substituted in the 1 position by the group R5, while R5 is as hereinbefore defined, a piperidin-4-yl group which is substituted in the 1 position by the group R5, while R5 is as hereinbefore defined, or a tetra hyd rofuran-3-yl, tetra hyd ro pyra n-3-yl or tetrahydropyran-4-yl group, Boehringer Ingelheim Pharma KG 5 Case 111317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Rd denotes a hydrogen atom or a fluorine, chlorine or bromine atom, a hydroxy group, a C1-4-alkyloxy group, a methoxy group substituted by 1 to 3 fluorine atoms, an ethyloxy group substituted by 1 to 5 fluorine atoms, a C2-4-alkyloxy group which is substituted by a group R6 or R7, while R6 is as hereinbefore defined and R7 denotes a hydroxy, C1-3-alkyloxy, C3-6-cycloalkyloxy, amino, C1-3-alkylamino, di-(C1-3-alkyl)amino, bis-(2-methoxyethyl)-amino, pyrrolidin-1-yl, piperidin-1-yl, homopiperidin-1-yl, morpholin-4-yl, homomorpholin-4-yl, 2-oxa-5-aza-bicyclo[2.2.1 ]hept-5-yl, 3-oxa-8-aza-bicyclo[3.2.1 ]oct-8-yl, 8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl, piperazin-1-yl, 4-C1.3-alkyl-piperazin-1-yl, homopiperazin-1-yl or C1-3-alkyl-homopiperazin-1-yl group, or a formylamino, C1-4-alkylcarbonylamino, C1-3-alkyloxy-C1-3-alkyl-carbonylamino, C1-4-alkyloxycarbonylamino, aminocarbonylamino, C1-3-alkylaminocarbonylamino, di-(C1-3-alkyl)aminocarbonylamino, pyrrolidin-1-ylcarbonylamino, piperidin-l-ylcarbonylamino, piperazin-1-ylcarbonylamino, 4-C1-3-alkyl-piperazin-1-ylcarbonylamino, morpholin-4-ylcarbonylamino or a C1.4-alkylsulphonylamino group, a C3-7-cycloalkyloxy or C3-7-cycloalkyl-Cl-4-alkyloxy group, a tetra hyd rofu ra n-3-yl oxy, tetra hyd ropyra n -3-yloxy or tetra hyd ropyran-4-yloxy group, Boehringer Ingelheim Pharma KG 6 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text a tetra hyd rofu ra nyl-C 1 -4-a lkyloxy or tetra hydropyranyl-C1 -alkyloxy group, a C1-4-alkoxy group which is substituted by a pyrrolidinyl, piperidinyl or homopiperidinyl group substituted in the 1 position by the group R8, while R8 denotes a hydrogen atom or a C1_3-alkyl group, or a C1.4-alkoxy groin, ~ which is substituted by a morpholinyl group substituted in the 4 position by the group R8, while R8 is as hereinbefore defined, and X denotes a methyne group substituted by a cyano group or a nitrogen atom, and by the aryl groups mentioned in the definition of the above groups is meant in each case a phenyl group which is mono- or disubstituted by R9, while the substituents may be identical or different and R9 denotes a hydrogen atom, a fluorine, chlorine, bromine or iodine atom or a C1_3-alkyl, hydroxy, C1.3-alkyloxy, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy or cyano group, by the heteroaryl groups mentioned in the definition of the above groups is meant a pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl group, while the abovementioned heteroaryl groups are each mono- or disubstituted by the group R9, while the substituents may be identical or different and R9 is as hereinbefore defined, and the abovementioned pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl groups may be substituted in each case by one or two C1.3-alkyl groups, and unless otherwise stated, the abovementioned alkyl groups may be straight-chained or branched, with the proviso that the compound 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-Boehringer Ingelheim Pharma KG 7 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text tetra hyd rofu ra n-3-yloxy)-7-hyd roxy-q u in azo I i ne is excluded.

Preferred compounds of the above general formula I are those wherein Ra denotes a hydrogen atom, Rb denotes a phenyl group substituted by the groups R' to R3, while R1 denotes a hydrogen, fluorine, chlorine or bromine atom, a methyl, trifluoromethyl or ethynyl group, a phenyloxy or phenylmethoxy group, while the phenyl moiety of the abovementioned groups is optionally substituted by a fluorine or chlorine atom, or a pyridyloxy or pyridinylmethoxy group, while the pyridinyl moiety of the abovementioned groups is optionally substituted by a methyl or trifluoromethyl group, R2 denotes a hydrogen, fluorine or chlorine atom or a methyl group and R3 denotes a hydrogen atom, R` denotes a cyclopentyl group which is substituted in the 3 position by a group R4-N-R5, while R4 denotes a hydrogen atom or a C1-3-alkyl group and R5 denotes a hydrogen atom or a C1_3-alkyl group, an aminocarbonyl-C1-3-alkyl, C1_3-alkylaminocarbonyl-C1_3-alkyl, di-(C1-3-alkyl)aminocarbonyl-C1.3-alkyl, pyrrolidin-1-ylcarbonyl-C1-3-alkyl, piperidin-1-ylcarbonyl-C1_3-alkyl, piperazin-1-ylcarbonyl-C1_3-alkyl, Boehringer Ingelheim Pharma KG 8 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text 4-C1_3-alkyl-piperazin-1-yl-carbonyl-C1_3-alkyl or morpholin-4-ylcarbonyl-C1_3-alkyl group, a hydroxy-C2-alkyl, C1_3-alkyloxy-C2.4-alkyl, C1_4-alkyloxy-carbonylamino-C24-alkyl, amino-C2-4-alkyl, C1_3-alkylamino-C2.4-alkyl, di-(C1.3-alkyl)amino-C2.4-alkyl, C1_3-alkylcarbonylamino-C2-4-alkyl, aminocarbonylamino-C2-4-alkyl, C1_3-alkylaminocarbonylamino-C2_4-alkyl, di-(C1.3-alkyl)amino-carbonylamino-C2-4-alkyl, morpholin-4-ylcarbonylamino-C2_4-alkyl, C1-3-alkylsulphonyI-C2_4-alkyl or C1_3-alkylsulphonylamino-C2_4-alkyl group, a (2-oxo-pyrrolidin-1-yl)-C24-alkyl, (2-oxopiperidin-1-yl)-C2-4-alkyl, (3-oxo-morpholin-4-yl)-C24-alkyl, (2-oxo-imidazolidin-1-yl)-C2_4-alkyl, (2-oxo-3-methyl-imidazolidin-1-yl)-C2.4-alkyl, (2-oxo-hexahydropyrimidin-1-yI)-C2-4-alkyl or (2-oxo-3-methyl-hexahydropyrimidin-1-yl)-C2-4-alkyl group, a C1-3-alkylsulphonyI, chloro-C2.4-alkylsulphonyI, bromo-C2.4-alkylsulphonyI, amino-C2-4-alkylsulphonyI, C1.3-alkylamino-C2.-alkylsulphonyI, di-(C1_3-alkyl)amino-C2_4-alkylsulphonyI, (pyrrolidin-1-yI)-C2-a-alkylsulphonyI, (piperidin-1-yl)-C2_4-alkylsulphonyI or (morpholin-4-yl)-C2-4-alkylsulphonyI group, a C1_4-alkyloxy-carbonyl group, a formyl, C1_3-alkyl-carbonyl, C1_3-alkyloxy-C1_3-alkyl-carbonyl, tetrahydrofuranylcarbonyl, tetrahydropyranylcarbonyl, amino-C1.3-alkyl-carbonyl, C1_3-alkylamino-C1_3-alkyl-carbonyl, di-(C1_3-alkyl)amino-C1_3-alkyl-carbonyl, pyrrolidin-1-yI-C1_3-alkyl-carbonyl, piperidin-1-yi-C1.3-alkyl-carbonyl, piperazin-1-yl-C1_3-alkyl-carbonyl, 4-C1_3-alkyl-piperazin-1-yl-C1.3-alkyl-carbonyl, morpholin-4-yl-C1.3-alkyl-carbonyl or a C1_3-alkylsulphonyI-C1.3-alkyl-carbonyl group, a cyano, aminocarbonyl, C1_3-alkyl-aminocarbonyl, di-(C1_3-alkyl)amino-Boehringer Ingelheim Pharma KG 9 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text carbonyl, (C1.3-alkyloxy-C2-4-alkyl)aminocarbonyl, N-(C1.3-alkyl)-N-(C1-3-alkyloxy-C2-4-alkyl)aminocarbonyl, phenylaminocarbonyl, pyrrolidin-l-ylcarbonyl, piperidin-l-ylcarbonyl, morpholin-4-ylcarbonyl, C1-3-alkyl-morpholin-4-ylcarbonyl, di-(C1_3-alkyl)morpholin-4-ylcarbonyl, homomorpholin-4-ylcarbonyl, 2-oxa-5-aza-bicyclo[2.2.1 ]hept-5-ylcarbonyl, 3-oxa-8-aza-bicyclo[3.2.1]oct-8-ylcarbonyl, 8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-ylcarbonyl, piperazin-1-ylcarbonyl, 4-(C1_3-alkyl)-piperazin-1-ylcarbonyl, aminosulphonyl, C1.3-alkyl-aminosulphonyl, di-(C1-3-alkyl)amino-sulphonyl, pyrrolidin-l-yl-sulphonyl, piperidin-l-ylsulphonyl or a morpholin-4-ylsulphonyl group, or a cyclopentyl group which is substituted in the 3 position by a group R6, while R6 denotes a 2-oxo-pyrrolidin-1-yl, 2-oxopiperidin-1-yl, 3-oxo-morpholin-4-yl, 2-oxo-imidazolidin-1-yl, 2-oxo-3-methyl-imidazolidin-1-yl, 2-oxo-hexahydropyrimidin-1-yl or a 2-oxo-3-methyl-hexahydropyrimidin-1-yl group, a cyclohexyl group which is substituted in the 3 position or in the 4 position by a group R4-N-R5, while R4 and R5 are as hereinbefore defined, a cyclohexyl group which is substituted in the 3 position or in the 4 position by a group R6, while R6 is as hereinbefore defined, a pyrrolidin-3-yl group which is substituted in the 1 position by the group R5, while R5 is as hereinbefore defined, a piperidin-3-yl group which is substituted in the 1 position by the group R5, while R5 is as hereinbefore defined, a piperidin-4-yl group which is substituted in the 1 position by the group R5, while R5 is as hereinbefore defined, or a tetrahydrofuran-3-yl, tetra hydropyran-3-yi or tetra hyd ropyra n -4-yl group, Boehringer Ingelheim Pharma KG 10 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Rd denotes a hydrogen atom, a C1_3-alkyloxy group, a methoxy group which is substituted by one to three fluorine atoms, an ethyloxy group which is substituted in the 2 position by a group R6 or R7, while R6 is as hereinbefore defined and R7 denotes a hydroxy, C1_3-alkyloxy, amino, C1_3-alkylamino, di-(C1.3-alkyl)amino, bis-(2-methoxyethyl)-amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, homomorpholin-4-yl, 2-oxa-5-aza-bicyclo[2.2.1 ]hept-5-yl, 3-oxa-8-aza-bicyclo[3.2.1 ]oct-8-yl, 8-oxa-3-aza-bicyclo[3.2. 1 ]oct-3-yl, piperazin- 1 -yl or a 4-C1_3-alkyl-piperazin-1-yl group, or a formylamino, C1-4-alkylcarbonylamino, C1_3-alkyloxy-C1_3-alkyl-carbonylamino, C1_4-alkyloxycarbonylamino, aminocarbonylamino, C1_3-alkylaminocarbonylamino, di-(C1.3-alkyl)aminocarbonylamino, pyrrolidin-1-ylcarbonylamino, piperidin-1-ylcarbonylamino, piperazin-1-ylcarbonylamino, 4-C1-3-alkyl-piperazin-1-ylcarbonylamino- morpholin-4-ylcarbonylamino or a C1-4-alkylsulphonylamino group, a propyloxy group which is substituted in the 3 position by a group R6 or R7, while R6 and R7 are as hereinbefore defined, or a butyloxy group which is substituted in the 4 position by a group R6 or R7, while R6 and R7 are as hereinbefore defined, and X denotes a nitrogen atom, while, unless stated otherwise, the abovementioned alkyl groups may be straight-chained or branched, Boehringer Ingelheim Pharma KG 11 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text their tautomers, their stereoisomers, their mixtures and their salts.

Particularly preferred compounds of the above general formula I are those wherein Ra denotes a hydrogen atom, Rb denotes a 3-ethynylphenyl, 3-bromophenyl, 3,4-difluorophenyl or 3-chioro-4-fluoro-phenyl group, a 3-chloro-4-benzyloxy-phenyl, 3-chloro-4-[(3-fluoro-benzyl)oxy]-phenyl, 4-(pyridin-3-yloxy)-phenyl, 4-[(6-methyl-pyridin-3-yl)oxy]-phenyl, 3-methyl-4-(pyridin-3-yloxy)-phenyl, 3-methyl-4-[(6-methyl-pyridin-3-yl)oxy]-phenyl, 3-chloro-4-(pyridin-3-yloxy)-phenyl or 3-chloro-4-[(6-methyl-pyridin-3-yl)oxy]-phenyl group, Rc denotes a cyclohexyl group which is substituted in the 3 position or in the position by a group R4-N-R5, while R4 denotes a hydrogen atom, a methyl or ethyl group and R5 denotes a hydrogen atom, a methyl, aminocarbonylmethyl, methylaminocarbonylmethyl, dimethylaminocarbonylmethyl, pyrrolidin-1-ylcarbonylmethyl, piperidin-1-ylcarbonylmethyl, piperazin-l -ylcarbonylmethyl, 4-methylpiperazin-1-ylcarbonylmethyl, morpholin-4-ylcarbonylmethyl, 2-(morpholin-4-yl-carbonyl)ethyl or 3-(morpholin-4-yl-carbonyl)propyl group, an ethyl, propyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, 2-(butyloxycarbonylamino)-ethyl, 2-aminoethyl, 3-aminopropyl, 2-(acetylamino)ethyl, 3-(acetylamino)propyl, 2-(ethylcarbonylamino)ethyl, 3-(ethylcarbonylamino)propyl, 2-(propylcarbonylamino)ethyl, 3-(propylcarbonylamino)propyl, 2-Boehringer Ingelheim Pharma KG 12 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (ethylaminocarbonylamino)ethyl, 3-(ethylaminocarbonylamino)propyl, 2-(dimethylaminocarbonylamino)ethyl, 3-(dimethylaminocarbonylamino)propyl, 2-(morpholin-4-ylcarbonylamino)ethyl, 3-(morpholin-4-ylcarbonylamino)propyl, 2-(methylsulphonyl)ethyl, 3-(methylsulphonyl)propyl, 2-(methylsulphonyl-amino)ethyl or a 3-(methylsulphonylamino)propyl group, a 2-(2-oxo-pyrrolidin-1-yI)ethyl, 2-(2-oxopiperidin-1-yi)ethyl, 2-(3-oxo-morpholin-4-yl)ethyl, 2-(2-oxo-imidazolidin-1-yl)ethyl, 2-(2-oxo-3-methyl-imidazolidin-1-yl)ethyl, 2-(2-oxo-hexahydropyrimidin-1-yl)ethyl or a 2-(2-oxo-3-methyl-hexahydropyrimidin-1-yl)ethyl group, a 3-(2-oxo-pyrrolidin-1-yl)propyl, 3-(2-oxopiperidin-1-yI)propyl, 3-(3-oxo-morpholin-4-yl)propyl, 3-(2-oxo-imidazolidin-1-yI)propyl, 3-(2-oxo-3-methyl-imidazolidin-1-yI)propyl, 3-(2-oxo-hexahydropyrimidin-1-yl)propyl or a 3-(2-oxo-3-methyl-hexahydropyrimidin-1-yI)propyl group, a methylsulphonyl, ethylsulphonyl, 3-chloropropylsulphonyl, 2-(morpholin-4-yl)-ethylsulphonyl or a 3-(morpholin-4-yl)-propylsulphonyl group, a propyloxycarbonyl or butyloxycarbonyl group, a formyl, acetyl, ethylcarbonyl, propylcarbonyl, methoxyacetyl, (2-methoxyethyl)carbonyl, (3-methoxypropyl)carbonyl, tetrahydrofuran-2-ylcarbonyl, tetrahydropyran-4-ylcarbonyl, aminoacetyl, methylaminoacetyl, dimethylaminoacetyl, morpholin-4-ylacetyl, [2-(morpholin-4-yl)ethyl]carbonyl, [3-(morpholin-4-yl)propyl]carbonyl or a methylsulphonylacetyl group, a cyano, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, ethylaminocarbonyl, diethylaminocarbonyl, propylaminocarbonyl, (2-methoxyethyl)aminocarbonyl, N-methyl-N-(2-methoxyethyl)-aminocarbonyl, (3-methoxypropyl)aminocarbonyl, N-methyl-N-(3-Boehringer Ingelheim Pharma KG 13 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text methoxypropyl)-aminocarbonyl, phenylaminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-l-ylcarbonyl, morpholin-4-ylcarbonyl, 2-methylmorpholin-4-ylcarbonyl, 2,6-dimethylmorpholin-4-ylcarbonyl, homomorpholin-4-ylcarbonyl, 2-oxa-5-aza-bicyclo[2.2.1 ]hept-5-ylcarbonyl, 3-oxa-8-aza-bicyclo[3.2.1 ]oct-8-ylcarbonyl, 8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, aminosulphonyl, methylaminosulphonyl, dimethylaminosulphonyl or a morpholin-4-ylsulphonyl group, a cyclohexyl group which is substituted in the 3 position or in the 4 position by a group R6, while R6 denotes a 2-oxo-pyrrolidin-1-yl, 2-oxopiperidin-1-yl, 3-oxo-morpholin-4-yl, 2-oxo-imidazolidin-1-yl, 2-oxo-3-methyl-imidazolidin-1-yl, 2-oxo-hexahydropyrimidin-1-yl or a 2-oxo-3-methyl-hexahydropyrimidin-1-yl group, a pyrrolidin-3-yl group which is substituted in the 1 position by the group R5, while R5 is as hereinbefore defined, a piperidin-3-yl group which is substituted in the 1 position by the group R5, while R5 is as hereinbefore defined, a piperidin-4-yl group which is substituted in the 1 position by the group R5, while R5 is as hereinbefore defined, a tetrahydrofuran-3-yl, tetrahydropyran-3-yl or tetrahydropyran-4-yl group, Rd denotes a hydrogen atom, a methoxy, difluoromethoxy or ethyloxy group, an ethyloxy group which is substituted in the 2 position by a group R6 or R7, while R6 is as hereinbefore defined and Boehringer Ingelheim Pharma KG 14 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text R7 denotes a hydroxy, methoxy, ethoxy, amino, dimethylamino, diethylamino, bis-(2-methoxyethyl)-amino, pyrrolidin-l-yl, piperidin-1-yl, morpholin-4-yl, homomorpholin-4-yl, 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl, 3-oxa-8-aza-bicyclo[3.2.1 ]oct-8-yl, 8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl, piperazin-l-yl, 4-methylpiperazin-1 -yl or 4-ethylpiperazin-1 -yl group, or an acetylamino, ethylcarbonylamino, propylcarbonylamino, butylcarbonylamino, methoxyacetylamino, butyloxycarbonylamino, ethylaminocarbonylamino, dimethylaminocarbonylamino, pyrrolidin-1-ylcarbonylamino, piperidin-l-ylcarbonylamino, morpholin-4-ylcarbonylamino, methylsulphonylamino, ethylsuiphonylamino or butylsulphonylamino group, a propyloxy group which is substituted in the 3 position by a group R6 or R7, while R6 and R7 are as hereinbefore defined, or a butyloxy group which is substituted in the 4 position by a group R6 or R7, while R6 and R7 are as hereinbefore defined, and X denotes a nitrogen atom, while, unless stated otherwise, the abovementioned alkyl groups may be straight-chained or branched, their tautomers, their stereoisomers, their mixtures and their salts.

Most particularly preferred compounds of general formula I are those wherein R8 denotes a hydrogen atom, Rb denotes a 3-bromophenyl, 3,4-difluorophenyl, 3-chloro-4-fluoro-phenyl or a 3-ethynylphenyl group, or Boehringer Ingelheim Pharma KG 15 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text a 3-chloro-4-benzyloxy-phenyl, 3-chloro-4-[(3-fluorbenzyl)oxy]-phenyl, 4-(pyridin-3-yloxy)-phenyl, 4-[(6-methyl-pyridin-3-yl)oxy]-phenyl, 3-methyl-4-(pyridin-3-yloxy)-phenyl, 3-methyl-4-[(6-methyl-pyridin-3-yl)oxy]-phenyl, 3-chloro-4-(pyridin-3-yloxy)-phenyl or 3-chloro-4-[(6-methyl-pyridin-3-yl)oxy]-phenyl group, R denotes a cyclohexyl group which is substituted in the 3 position by an amino, acetylamino, tert.-butyloxycarbonylamino or methylsuiphonylamino group, a cyclohexyl group which is substituted in the 4 position by an amino, methylamino, ethylamino, dimethylamino, aminocarbonylmethylamino, methylaminocarbonylmethylamino, dimethylaminocarbonylmethylamino, morpholin-4-ylcarbonylmethylamino, [3-(morpholin-4-ylcarbonyl)propyl]amino, [2-(methylsulphonyl)ethyl]amino, [3-(methylsulphonyl)propyl]amino or [2-(methylsulphonylamino)ethyl]amino group, a cyclohexyl group which is substituted in the 4 position by a [2-(2-oxo-pyrrolidin-1-yl)ethyl]amino, [2-(2-oxopiperidin-1-yl)ethyl]amino, [2-(2-oxo-imidazolidin-1-yl)ethyl]amino, [2-(2-oxo-3-methyl-imidazolidin-1-yl)ethyl]amino, [2-(2-oxo-hexahydropyrimidin-1-yl)ethyl]amino or [2-(2-oxo-3-methyl-hexahydropyrimidin-1-yi)ethyl]amino group, a cyclohexyl group which is substituted in the 4 position by a [3-(2-oxo-pyrrolidin-1-yl)propyl]amino, [3-(2-oxopiperidin-1-yl)propyl]amino, [3-(2-oxo-imidazolidin-1-yl)propyl]amino, [3-(2-oxo-3-methyl-imidazolidin-1-yl)propyl]amino, [3-(2-oxo-hexahydropyrimidin-1 -yl)propyl]amino or [3-(2-oxo-3-methyl-hexahydropyrimidin-1-yl)propyl]amino group, a cyclohexyl group which is substituted in the 4 position by an acetylamino, N-(acetyl)-methylamino, aminomethylcarbonylamino, methylaminomethylcarbonylamino, dimethylaminomethylcarbonylamino, morpholin-4-ylmethylcarbonylamino, methoxyacetylamino, N-(methoxyacetyl)-Boehringer Ingelheim Pharma KG 16 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text methylamino, tetrahydropyran-4-ylcarbonylamino, N-(tetrahydropyran-4-ylcarbonyl)-methylamino, tert.-butyloxycarbonylamino, N-(tert.-butyloxycarbonyl)-methylamino, aminocarbonylamino, methylaminocarbonylamino, N-(ethylaminocarbonyl)-methylamino, dimethylaminocarbonylamino, N-(dimethylaminocarbonyl)-methylamino, N-(piperidin-1-ylcarbonyl)-methylamino, morpholin-4-ylcarbonylamino, N-(morpholin-4-ylcarbonyl)-methylamino or N-(4-methylpiperazin-1-ylcarbonyl)-methylamino group, a cyclohexyl group which is substituted in the 4 position by a 2-oxo-pyrrolidin-1-yl, 2-oxopiperidin-1-yl, 3-oxo-morpholin-4-yl, 2-oxo-imidazolidin-1-yl, 2-oxo-3-methyl-imidazolidin-1-yl, 2-oxo-hexahydropyrimidin-1-yl or a 2-oxo-3-methyl-hexahydropyrimidin-1-yl group, a cyclohexyl group which is substituted in the 4 position by a methylsulphonylamino, N-(methylsulphonyl)-methylamino, ethylsulphonylamino, N-(ethylsulphonyl)-methylamino, dimethylaminosulphonylamino, N-(dimethylaminosulphonyl)-methylamino, morpholin-4-ylsulphonylamino, N-(morpholin-4-ylsulphonyl)-methylamino- 3-chloropropylsulphonylamino, [2-(morpholin-4-yl)-ethyl]sulphonylamino or [3-(morpholin-4-yl)-propyl]sulphonylamino- group, a pyrrolidin-3-yl group, a pyrrolidin-3-yl group which is substituted in the 1 position by a methyl, acetyl, methoxyacetyl, tert.-butyloxycarbonyl, morpholin-4-ylcarbonyl or methylsulphonyl group, a piperidin-3-yl group, a piperidin-3-yl group which is substituted in the 1 position by a methyl, acetyl, methoxyacetyl, tert.-butyloxycarbonyl, morpholin-4-ylcarbonyl or methylsulphonyl group, Boehringer Ingelheim Pharma KG 17 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text a piperidin-4-yl group which is substituted in the 1 position by a methyl, ethyl, propyl, isopropyl, 2-hydroxyethyl, 2-methoxyethyl, 3-methoxypropyl, 2-(methylsulphonyl)-ethyl, 3-(methylsulphonyl)-propyl, 2-(tert.-butyloxycarbonylamino)-ethyl, 2-aminoethyl, 2-(acetylamino)-ethyl, 2-(ethylcarbonylamino)-ethyl, 2-(propylcarbonylamino)-ethyl, 2-(ethylaminocarbonylamino)-ethyl, 2-(dimethylaminocarbonylamino)-ethyl, 2-(morpholin-4-ylcarbonylamino)-ethyl, 3-(acetylamino)-propyl, 3-(ethylcarbonylamino)-propyl, 3-(propylcarbonylamino)-propyl, 3-(ethylaminocarbonylamino)-propyl, 3-(dimethylaminocarbonylamino)-propyl, 3-(morpholin-4-ylcarbonylamino)-propyl, 2-(methylsulphonylamino)-ethyl, 3-(methylsulphonylamino)-propyl, (aminocarbonyl)methyl, (methylaminocarbonyl)methyl, (dimethylaminocarbonyl)methyl, (pyrrolidin-1-ylcarbonyl)methyl, (morpholin-4-ylcarbonyl)methyl, 2-(morpholin-4-ylcarbonyl)-ethyl or 3-(morpholin-4-ylcarbonyl)-propyl group, a piperidin-4-yl group which is substituted in the 1 position by a 2-(2-oxo-pyrrolidin-1-yl)-ethyl, 2-(2-oxopiperidin-1-yl)-ethyl, 2-(3-oxomorpholin-4-yl)-ethyl, 2-(2-oxo-imidazolidin-1-yl)-ethyl, 2-(2-oxo-3-methyl-imidazolidin-1-yl)-ethyl, 2-(2-oxo-hexahydropyrimidin-1-yl)-ethyl or 2-(2-oxo-3-methyl-hexahydropyrimidin-1-yl)-ethyl group, a piperidin-4-yl group which is substituted in the 1 position by a 3-(2-oxo-pyrrolidin-1-yl)-propyl, 3-(2-oxopiperidin-1-yl)-propyl, 3-(3-oxomorpholin-4-yl)-propyl, 3-(2-oxo-imidazolidin-1-yl)-propyl, 3-(2-oxo-3-methyl-imidazolidin-1-yl)-propyl, 3-(2-oxo-hexahydropyrimidin-1-yl)-propyl or 3-(2-oxo-3-methyl-hexahydropyrimidin-1-yl)-propyl group, a piperidin-4-yl group which is substituted in the 1 position by a formyl, acetyl, methoxyacetyl, (2-methoxyethyl)carbonyl, (3-methoxypropyl)carbonyl, methylsulphonylacetyl, aminoacetyl, methylaminoacetyl, (dimethylamino)acetyl, (morpholin-4-yl)acetyl, [2-(morpholin-4-yl)-ethyl]carbonyl, [3-(morpholin-4-yl)-propyl]carbonyl, tetrahydrofuran-2-ylcarbonyl or tetrahydropyran-4-ylcarbonyl group, Boehringer Ingelheim Pharma KG 18 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text a piperidin-4-yl group which is substituted in the 1 position by a cyano, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, (2-methoxyethyl)aminocarbonyl, N-methyl-N-(2-methoxyethyl)-aminocarbonyl, (3-methoxypropyl)aminocarbonyl, N-methyl-N-(3-methoxypropyl)-aminocarbonyl, isopropylaminocarbonyl, phenylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, 2-methylmorpholin-4-ylcarbonyl, 2,6-dimethylmorpholin-4-ylcarbonyl, homomorpholin-4-ylcarbonyl, 2-oxa-5-aza-bicyclo[2.2.1 ]kept-5-ylcarbonyl, 3-oxa-8-aza-bicyclo[3.2.1 ]oct-8-ylcarbonyl, 8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, isopropyloxycarbonyl or tert.-butyloxycarbonyl group, a piperidin-4-yl group which is substituted in the 1 position by a methylsuiphonyl, ethylsulphonyl, [2-(morpholin-4-yl)-ethyl]sulphonyl, [3-(morpholin-4-yl)-propyl]sulphonyl, aminosuiphonyl, methylaminosulphonyl, dimethylaminosuiphonyl or morpholin-4-ylsulphonyl group, or a tetrahydrofuran-3-yl, tetra hyd ropyra n-3-yl or tetra hyd ro pyra n-4-yl group, Rd denotes a hydrogen atom, a methoxy, difluoromethoxy or ethyloxy group, a 2-(morpholin-4-yl)ethyloxy, 3-(morpholin-4-yi)propyloxy or 4-(morpholin-4-yl)butyloxy group, a 3-(dimethylamino)propyloxy, 3-(d iethylamino)propyloxy, 3-[bis-(2-methoxyethyl)-amino]propyloxy, 3-(piperazin-1-yl)propyloxy, 3-(4-methylpiperazin-1-yl)propyloxy or 3-(4-ethylpiperazin-1-yl)propyloxy group, a 3-(homomorpholin-4-yl)-propyloxy, 3-(2-oxa-5-aza-bicyclo[2.2.1 ]hept-5-yl)-propyloxy, 3-(3-oxa-8-aza-bicyclo[3.2.1]oct-8-yl)-propyloxy or 3-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-propyloxy group, Boehringer Ingelheim Pharma KG 19 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text a 2-(2-oxo-pyrrolidin-1-yl)-ethyloxy, 2-(2-oxopiperidin-1-yl)-ethyloxy, 2-(3-oxomorpholin-4-yi)-ethyloxy, 2-(2-oxo-imidazolidin-1-yl)-ethyloxy, 2-(2-oxo-3-methyl-imidazolidin-l -yl)-ethyloxy, 2-(2-oxo-hexahydropyrimidin-1-yl)-ethyloxy or 2-(2-oxo-3-methyl-hexahydropyrimidin-1-yl)-ethyloxy group, a 3-(2-oxo-pyrrolidin-1-yl)-propyloxy, 3-(2-oxopiperidin-1-yl)-propyloxy, 3-(3-oxomorpholin-4-yl)-propyloxy, 3-(2-oxo-imidazolidin-1-yl)-propyloxy, 3-(2-oxo-3-methyl-imidazolidin-1-yl)-propyloxy, 3-(2-oxo-hexahydropyrimidin-1-yl)-propyloxy or 3-(2-oxo-3-methyl-hexahydropyrimidin-1-yl)-propyloxy group, a 2-(methoxy)-ethyloxy, 2-(tert.-butyloxycarbonylamino)-ethyloxy, 2-(amino)-ethyloxy, 2-(acetylamino)-ethyloxy, 2-(ethylcarbonylamino)-ethyloxy, 2-(propylcarbonylamino)-ethyloxy, 2-(isobutylcarbonylamino)-ethyloxy, 2-(methoxyacetylamino)-ethyloxy, 2-(ethylaminocarbonylamino)-ethyloxy, 2-(dimethylaminocarbonylamino)-ethyloxy, 2-(pyrrolidin-1-ylcarbonylamino)-ethyloxy, 2-(piperidin-1 -ylcarbonylamino)-ethyloxy, 2-(morpholin-4-ylcarbonylamino)-ethyloxy, 2-(methylsulphonylamino)-ethyloxy group, 2-(ethylsulphonylamino)-ethyloxy or 2-(butylsulphonylamino)-ethyloxy group, or a 3-(tert.-butyloxycarbonylamino)-propyloxy, 3-(amino)-propyloxy, 3-(acetylamino)-propyloxy or 3-(methylsulphonylamino)-propyloxy group, and X denotes a nitrogen atom, their tautomers, their stereoisomers, their mixtures and their salts.
Particularly preferred compounds of general formula I are those wherein Ra denotes a hydrogen atom, Rb preferably denotes a 3-chloro-4-fluoro-phenyl group or also a 3-ethynyiphenyl group, Boehringer Ingelheim Pharma KG 20 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Rc denotes a cyclohexyl group which is substituted in the 3 position by an amino, acetylamino, tert.-butyloxycarbonylamino or methylsulphonylamino group, a cyclohexyl group which is substituted in the 4 position by an amino, methylamino, dimethylamino, acetylamino, N-(acetyl)-methylamino, methoxyacetylamino, N-(methoxyacetyl)-methylamino, tetrahydropyran-4-ylcarbonylamino, N-(tetrahydropyran-4-ylcarbonyl)-methylamino, tert.-butyloxycarbonylamino, N-(tert.-butyloxycarbonyl)-methylamino, N-(ethylaminocarbonyl)-methylamino, dimethylaminocarbonylamino, N-(d imethylaminocarbonyl)-methylamino, N-(piperidin-1-ylcarbonyl)-methylamino, morpholin-4-ylcarbonylamino, N-(morpholin-4-ylcarbonyl)-methylamino, N-(4-methylpiperazin-1-ylcarbonyl)-methylamino, methylsulphonylamino, N-(methylsulphonyl)-methylamino, ethylsulphonylamino, N-(ethylsulphonyl)-methylamino, dimethylaminosulphonylamino, N-(dimethylaminosulphonyl)-methylamino, morpholin-4-ylsulphonylamino, N-(morpholin-4-ylsulphonyl)-methylamino, 3-chloropropylsuiphonylamino, or [3-(morpholin-4-yi)-propyl]sulphonylamino group, a pyrrolidin-3-yl group, a pyrrolidin-3-yl group which is substituted in the 1 position by a tert.-butyloxycarbonyl or methylsulphonyl group, a piperidin-3-yl group, a piperidin-3-yl group which is substituted in the 1 position by a tert.-butyloxycarbonyl or methylsulphonyl group, a piperidin-4-yl group, a piperidin-4-yl group which is substituted in the 1 position by a methyl, Boehringer Ingelheim Pharma KG 21 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (aminocarbonyl)methyl, (d imethylaminocarbonyl)methyl, (morpholin-4-ylcarbonyl)methyl, 2-(tert.-butyloxycarbonylamino)ethyl, 2-aminoethyl, 2-(acetylamino)ethyl, 2-(methylsulphonylamino)ethyl, cyano, acetyl, methoxyacetyl, (dimethylamino)acetyl, (morpholin-4-yl)acetyl, tetrahydropyran-4-ylcarbonyl, ethylaminocarbonyl, isopropylaminocarbonyl, phenylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, 2-methylmorpholin-4-ylcarbonyl, 2,6-dimethylmorpholin-4-ylcarbonyl, homomorpholin-4-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, isopropyloxycarbonyl, tert.-butyloxycarbonyl, methylsulphonyl, dimethylaminosulphonyl or morpholin-4-ylsulphonyl group, or a tetrahydrofuran-3-yl, tetra hyd ropyra n-3-yl or tetra h yd ropyra n-4-yl group, Rd denotes a hydrogen atom, a methoxy or ethyloxy group, a 2-(morpholin-4-yl)ethyloxy, 3-(morpholin-4-yl)propyloxy or 4-(morpholin-4-yl)butyloxy group, a 2-(3-methyl-2-oxo-hexahydropyrimidin-1-yl)-ethyloxy group, a 2-(methoxy)-ethyloxy, 2-(tert.-butyloxycarbonylamino)-ethyloxy, 2-amino-ethyloxy, 2-(acetylamino)-ethyloxy or 2-(methylsulphonylamino)-ethyloxy group or a 3-(tert.-butyloxycarbonylamino)-propyloxy, 3-amino-propyloxy, 3-(acetylamino)-propyloxy or 3-(methylsulphonylamino)-propyloxy group, and X denotes a nitrogen atom, Boehringer Ingelheim Pharma KG 22 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text their tautomers, their stereoisomers, their mixtures and their salts.

Of the bicyclic heterocyclic groups of general formula I as described above as well as the sub-groups specified as being preferred, particularly preferred, most particularly preferred and especially preferred, special mention should be made of those compounds wherein (a) R denotes a cyclohexyl group substituted in the 4 position, (b) Rc denotes a pyrrolidin-3-yl group optionally substituted in the 1 position, (c) Rc denotes a piperidin-3-yl group optionally substituted in the 1 position, (d) Rc denotes a piperidin-4-yl group optionally substituted in the 1 position, (e) Rc denotes a tetrahydrofuran-3-yl group, (f) Rcdenotes a tetrahydropyran-3-yl group, or (g) R` denotes a tetrahydropyran-4-yl group, while Ra, Rb, Rd and X in each case are as hereinbefore defined.

The following are mentioned as examples of particularly preferred compounds of general formula I:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-meth oxy-q u i n azol i ne, (2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-methoxy-quinazoline, (3) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((R)-tetrahydrofuran-3-yloxy)-7-methoxy-quinazoline, Boehringer Ingelheim Pharma KG 23 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (4) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-amino-cyclohexane-1-yloxy)-7-methoxy-quinazoline, (5) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methanesulphonylamino-cyclohexane-1-yloxy)-7-methoxy-quinazoline, (6) 4-[(3-chIoro-4-f1 uoro-phenyl)amino]-6-(piperidin-4-yloxy)-7-methoxy-quinazoline, (7) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, (8) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{[3-(morpholin-4-yl)-propyl]sulphonylamino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline, (9) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-3-yloxy)-7-methoxy-quinazoline, (10) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-{[3-(morpholin-4-yl)-propyl]sulphonylamino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline, (11) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline, (12) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yI)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, (13) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(methoxymethyl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, (14) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline, Boehringer Ingelheim Pharma KG 24 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (15) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)sulphonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, (16) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-acetylamino-ethyl)-piperidin-4-yloxy]-7-methoxy-quinazoline, (17) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(dimethylamino)sulphonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline, (18) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline, (19) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(morpholin-4-yl)sulphonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline, (20) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-acetylamino-ethoxy)-quinazoline, (21) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-methanesulphonylamino-ethoxy)-quinazoline and (22) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline, as well as their salts.

The compounds of general formula I may be prepared for example by the following methods:

a) reacting a compound of general formula Boehringer Ingelheim Pharma KG 25 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text RNRb O-H
N Rd ,(II) wherein Ra, Rb, Rd and X are as hereinbefore defined, with a compound of general formula Z' - Rc ,(III) wherein Rc is as hereinbefore defined and Z' denotes a leaving group such as a halogen atom, e.g. a chlorine or bromine atom, a suiphonyloxy group such as a methanesuiphonyloxy or p-toluenesulphonyloxy group or a hydroxy group.
With a compound of general formula III wherein Z' denotes a hydroxy group, the reaction is carried out in the presence of a dehydrating agent, preferably in the presence of of a phosphine and an azodicarboxylic acid derivative such as e.g. triphenylphosphine/diethyl azodicarboxylate, conveniently in a solvent such as methylene chloride, acetonitrile, tetrahydrofuran, dioxane, toluene or ethylenglycoldiethylether at temperatures between -50 and 150 C, but preferably at temperatures between -20 and 80 C.

b) In order to prepare compounds of general formula I wherein Rd denotes one of the optionally substituted alkyloxy groups mentioned hereinbefore:
reacting a compound of general formula Boehringer Ingelheim Pharma KG 26 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text b R\N,R

O,R
X

N O-H
,(IV) wherein Ra, Rb, R and X are as hereinbefore defined, with a compound of general formula Z2 - Rd, 'M

wherein Rd' denotes a C1_4-alkyl group, a methyl group substituted by 1 to 3 fluorine atoms, an ethyl group substituted by 1 to 5 fluorine atoms, a C2-4-alkyl group substituted by a group R6 or R7, where R6 and R7 are as hereinbefore defined, a C1-a-alkyl group which is substituted by a pyrrolidinyl, piperidinyl or homopiperidinyl group substituted in the 1 position by the group R8, or a C1_4-alkyl group which is substituted by a morpholinyl group substituted in the 4 position by the group R8, while R8 in each case is as hereinbefore defined, and Z2 denotes a leaving group such as a halogen atom, an alkylsulphonyloxy, arylsulphonyloxy or a hydroxy group.

If the leaving group is a halogen atom such as a chlorine, bromine or iodine atom or an alkylsulphonyloxy or arylsulphonyloxy group such as the methanesulphonyloxy or p-toluenesulphonyloxy group, the reaction is preferably carried out in the presence of an organic or inorganic base such as potassium carbonate, sodium hydride or N-ethyl-diisopropylamine. If the leaving group is a hydroxy group, the reaction is carried out in the presence of a dehydrating agent, preferably in the presence of a phosphine and an azodicarboxylic acid derivative such as e.g. triphenylphosphine/diethyl azodicarboxylate.

c) In order to prepare compounds of general formula I wherein Rd denotes Boehringer Ingelheim Pharma KG 27 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text one of the abovementioned alkyloxy groups which is substituted by an optionally substituted amino, alkylamino or dialkylamino group or by an optionally substituted heterocyclic group bound via an iminonitrogen atom:
reacting a compound of general formula Ra\N~ Rb O
X Rc ki" N O-(CH2)2-4-Z3 (VI), wherein Ra, Rb, Rc and X are as hereinbefore defined and Z3 denotes a leaving group such as a halogen atom, e.g. a chlorine or bromine atom or a sulphonyloxy group such as a methanesulphonyloxy or p-toluenesulphonyloxy group, with ammonia, a corresponding, optionally substituted alkylamine, dialkylamine or an imino compound or the suitable salts or derivatives thereof, such as morpholine, for example.

d) In order to prepare compounds of general formula I wherein Rd denotes a hydroxy group:

Cleaving a protecting group from a compound of general formula RaRb X O Rc IRd" (VII), wherein Ra, Rb, Rc and X are as hereinbefore defined and Rdõ denotes a group which may be converted into a hydroxy group, for example an Boehringer Ingelheim Pharma KG 28 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text optionally substituted benzyloxy group, a trimethylsilyloxy, acetyloxy, benzoyloxy, methoxy, ethoxy, tert-butoxy or trityloxy group.

The protecting group is cleaved for example by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxan/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide or aprotically, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 C, preferably at temperatures between 10 and 100 C.
However, a benzyl or methoxybenzyl group is cleaved, for example, hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100 C, but preferably at ambient temperatures between 20 and 60 C, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar. A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisole.

A tert.butyl or benzyl group is cleaved for example by treating with an acid such as trifluoroacetic acid, hydrochloric acid or hydrobromic acid or by treating with iodotrimethylsilane, optionally using a solvent such as methylene chloride, dioxan, methanol or diethyl ether.

e) In order to prepare compounds of general formula I wherein Rc contains a -NH- group:

cleaving a protecting group from a compound of general formula Ra Rb X RC
N Rd (VIII), Boehringer Ingelheim Pharma KG 29 Case 111317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text wherein Ra, Rb, Rd and X are as hereinbefore defined and R ' has the meanings given for R hereinbefore, with the proviso that R contains a protected nitrogen atom.

Conventional protecting groups for an amino, alkylamino or imino group are for example the formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert.-butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group, while for the amino group the phthalyl group is an additional possibility.

The protecting group is cleaved for example by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxan/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide or aprotically, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 C, preferably at temperatures between 10 and 100 C.
However, a benzyl, methoxybenzyl or benzyloxycarbonyl group is cleaved, for example hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100 C, but preferably at ambient temperatures between 20 and 60 C, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar. A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisole.

A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid or by treating with iodotrimethylsilane optionally using a solvent such as methylene chloride, dioxan, methanol or diethyl ether.

Boehringer Ingelheim Pharma KG 30 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text A trifluoroacetyl group is preferably cleaved by treating with an acid such as hydrochloric acid, optionally in the presence of a solvent such as acetic acid at temperatures between 50 and 120 C or by treating with sodium hydroxide solution, optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0 and 50 C.

A phthalyl group is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene/water or dioxane at temperatures between 20 and 50 C.

f) In order to prepare compounds of general formula I wherein R` contains an alkyl group substituted by an optionally substituted amino, alkylamino or dialkyamino group or by an optionally substituted heterocyclic group bound via a nitrogen atom:

reacting a compound of general formula R \N,Rb X ~, O
Rcõ Z3 N Rd (IX), wherein Ra, Rb, Rd and X are as hereinbefore defined, Z3 denotes a leaving group, for example a halogen atom such as a chlorine or bromine atom, or a sulphonyloxy group such as a methanesulphonyloxy or p-toluenesulphonyloxy group, and Rc" has the meanings given for Rc hereinbefore with the proviso that a hydrogen atom bound to an aliphatic carbon atom is replaced by the group Z3, with ammonia, a corresponding, optionally substituted alkylamine, dialkylamine or an imino compound or the appropriate salts or derivatives thereof, such as morpholine, for example.

Boehringer Ingelheim Pharma KG 31 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text If according to the invention a compound of general formula I is obtained which contains an amino, alkylamino or imino group, this may be converted by acylation, cyanation or sulphonylation into a corresponding acyl, cyano or sulphonyl compound of general formula I, the acylating agents being for example isocyanate, carbamoyl chloride, carboxylic acid halide, carboxylic acid anhydride and carboxylic acids with activating agents such as N,N'-carbonyldiimidazole, N,N'-dicyclohexylcarbodiimide or O-(benzotriazol-1-yl)-N,N,N'N'-tetramethyluronium-tetrafluoroborate, the sulphonylating agents being sulphonyl halides and the cyanating agents being chlorine or bromocyanogen, and/or if a compound of general formula I is obtained which contains an amino, alkylamino or imino group, this may be converted by alkylation or reductive alkylation into a corresponding alkyl compound of general formula I and/or if a compound of general formula I is obtained which contains a chloro-CI_4-alkylsulphonyl or bromo-C1_4-alkylsulphonyl group, this may be converted by reaction with an amine into a corresponding amino-Ci-4-alkylsulphonyl compound and/or if a compound of general formula I is obtained which contains a tert.-butyloxycarbonylamino, N-alkyl-N-(tert.-butyloxycarbonyl)amino or a N-tert.-butyloxycarbonylimino group, this may be converted into a corresponding amino, alkylamino or imino compound of general formula I by treatment with an acid such as hydrochloric acid or trifluoroacetic acid.

In the reactions described hereinbefore, any reactive groups present such as hydroxy, carboxy or imino groups may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.
For example, a protecting group for a hydroxy group may be a trimethylsilyl, acetyl, trityl, benzyl or tetrahydropyranyl group.

Boehringer Ingelheim Pharma KG 32 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Protecting groups for an amino, alkylamino or imino group may be a formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert.butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group, for example.

Any protecting group used is optionally subsequently cleaved for example by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxan/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide or aprotically, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 C, preferably at temperatures between 10 and 100 C.

However, a benzyl, methoxybenzyl or benzyloxycarbonyl group is cleaved, for example, hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100 C, but preferably at ambient temperatures between 20 and 60 C, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar. A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisole.

A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid or by treating with iodotrimethylsilane optionally using a solvent such as methylene chloride, dioxan, methanol or diethyl ether.

A trifluoroacetyl group is preferably cleaved by treating with an acid such as hydrochloric acid, optionally in the presence of a solvent such as acetic acid at temperatures between 50 and 120 C or by treating with sodium hydroxide solution, optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0 and 50 C.

Boehringer Ingelheim Pharma KG 33 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Moreover, the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers, as mentioned hereinbefore. Thus, for example, cis/trans mixtures may be resolved into their cis and trans isomers, and compounds with at least one optically active carbon atom may be separated into their enantiomers.

Thus, for example, the cis/trans mixtures may be resolved by chromatography into the cis and trans isomers thereof, the compounds of general formula I
obtained which occur as racemates may be separated by methods known per se (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.

The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents.
Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+) or (-)-menthol and an optically active acyl group in amides, for example, may be a (+)-or (-)-menthyloxycarbonyl.

Furthermore, the compounds of formula I may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable Boehringer Ingelheim Pharma KG 34 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, methanesuiphonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.

The compounds of general formulae II to I used as starting materials are known from the literature in some cases or may be obtained by methods known from the literature (cf. Examples I to XXII) or the methods described hereinbefore, optionally with the additional use of protecting groups (e.g.
compounds of formula IV or VII and VIII).

As already mentioned hereinbefore, the compounds of general formula I
according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by the Epidermal Growth Factor receptor (EGF-R), whilst this may be achieved for example by inhibiting ligand bonding, receptor dimerisation or tyrosine kinase itself. It is also possible that the transmission of signals to components located further down is blocked.
The biological properties of the new compounds were investigated as follows:
The inhibition of human EGF-receptor kinase was determined using the cyto-plasmic tyrosine kinase domain (methionine 664 to alanine 1186 based on the sequence published in Nature 309 (1984), 418). For this the protein was expressed in Sf9 insect cells as GST fusion protein using the Baculovirus expression system.

The enzyme activity was measured in the presence or absence of the test compounds in serial dilutions. The polymer pEY (4:1) obtained from SIGMA
was used as the substrate. Biotinylated pEY (bio-pEY) was added as the tracer substrate. 100 pI of reaction solution contained 10 pl of the inhibitor in 50% DMSO, 20 pl of the substrate solution (200 mM HEPES pH 7.4, 50 mM
magnesium acetate, 2.5 mg/ml poly(EY), 5 pg/ml bio-pEY) and 20 pl of enzyme preparation. The enzyme reaction was started by the addition of 50 pl Boehringer Ingelheim Pharma KG 35 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text of a 100 pM ATP solution in 10 mM of magnesium chloride. The dilution of the enzyme preparation was adjusted so that the incorporation of phosphate in the bio-pEY was linear in terms of time and quantity of enzyme. The enzyme preparation was diluted in 20 mM HEPES pH 7.4, 1 mM EDTA, 130 mM
common salt, 0.05% Triton X-100, 1 mM DTT and 10% glycerol.

The enzyme assays were carried out at ambient temperature over a period of 30 minutes and ended by the addition of 50 pl of a stopping solution (250 mM
EDTA in 20 mM HEPES pH 7.4). 100 pl were placed on a streptavidine-coated microtitre plate and incubated for 60 minutes at ambient temperature.
Then the plate was washed with 200 pl of a wash solution (50 mM Tris, 0.05%
Tween 20). After the addition of 100 pl of an HRPO-labelled anti-PY antibody (PY20H Anti-PTyr:HRP made by Transduction Laboratories, 250 ng/ml) the preparation was incubated for 60 minutes. Then the microtitre plate was washed three times with 200 pl of wash solution. The samples were then combined with 100 pl of a TMB-peroxidase solution (A:B = 1:1, Kirkegaard Perry Laboratories). After 10 minutes the reaction was stopped. The extinction was measured at OD45onm with an ELISA reader. All the results were measured three times.

The data were adapted by iterative calculation using an analytical pogramme for sigmoidal curves (Graph Pad Prism Version 3.0) with a variable Hill pitch.
All the iterative data produced had a correlation coefficient of more than 0.9 and the upper and lower values of the curves showed a spread of at least a factor of 5. The active substance concentration which inhibits the activity of EGF receptor kinase by 50% (IC50) was derived from the curves.

Boehringer Ingelheim Pharma KG 36 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text The following results were obtained:

Compound Inhibition of EGF-(Example Nr.) receptor kinase IC50 [nM]

1 0.13 1(1) 0.12 1(2) 2 1(3) 1.1 1(4) 0.6 1(5) 0.6 1(6) 0.69 1(7) 1.6 2 4.5 2(1) 0.16 2(2) 0.22 3 0.9 3(1) 0.14 3(2) 0.22 3(7) 0.7 3(8) 0.6 3(9) 0.2 3(11) 0.1 3(15) 1 3(16) 1 3(17) 0.3 3(18) 0.4 3(20) 1 3(21) 0.4 4 0.41 4(1) 0.16 7(5) 1 Boehringer Ingelheim Pharma KG 37 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text The compounds of general formula I according to the invention thus inhibit signal transduction by tyrosine kinases, as demonstrated by the example of the human EGF receptor, and are therefore useful for treating pathophysiological processes caused by hyperfunction of tyrosine kinases.
These are e.g. benign or malignant tumours, particularly tumours of epithelial and neuroepithelial origin, metastasisation and the abnormal proliferation of vascular endothelial cells (neoangiogenesis).

The compounds according to the invention are also useful for preventing and treating diseases of the airways and lungs which are accompanied by increased or altered production of mucus caused by stimulation by tyrosine kinases, e.g. in inflammatory diseases of the airways such as chronic bronchitis, chronic obstructive bronchitis, asthma, bronchiectasis, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, al-antitrypsin deficiency, or coughs, pulmonary emphysema, pulmonary fibrosis and hyperreactive airways.

The compounds are also suitable for treating diseases of the gastrointestinal tract and bile duct and gall bladder which are associated with disrupted activity of the tyrosine kinases, such as may be found e.g. in chronic inflammatory changes such as cholecystitis, Crohn's disease, ulcerative colitis, and ulcers in the gastrointestinal tract or such as may occur in diseases of the gastrointestinal tract which are associated with increased secretions, such as Menetrier's disease, secreting adenomas and protein loss syndrome.

In addition, the compounds of general formula I and the physiologically acceptable salts thereof may be used to treat other diseases caused by abnormal function of tyrosine kinases, such as e.g. epidermal hyperproliferation (psoriasis), benign prostate hyperplasia (BPH), inflammatory processes, diseases of the immune system, hyperproliferation of haematopoietic cells, the treatment of nasal polyps, etc.

Boehringer Ingelheim Pharma KG 38 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text By reason of their biological properties the compounds according to the invention may be used on their own or in conjunction with other pharmacologically active compounds, for example in tumour therapy, in monotherapy or in conjunction with other anti-tumour therapeutic agents, for example in combination with topoisomerase inhibitors (e.g. etoposide), mitosis inhibitors (e.g. vinblastine), compounds which interact with nucleic acids (e.g.
cis-platin, cyclophosphamide, adriamycin), hormone antagonists (e.g.
tamoxifen), inhibitors of metabolic processes (e.g. 5-FU etc.), cytokines (e.g.
interferons), antibodies, etc. For treating respiratory tract diseases, these compounds may be used on their own or in conjunction with other therapeutic agents for the airways, such as substances with a secretolytic (e.g. ambroxol, N-acetylcysteine) , broncholytic (e.g. tiotropium or ipratropium or fenoterol, salmeterol, salbutamol) and/or anti-inflammatory activity (e.g. theophylline or glucocorticoids). For treating diseases in the region of the gastrointestinal tract, these compounds may also be administered on their own or in conjunction with substances having an effect on motility or secretion. These combinations may be administered either simultaneously or sequentially.
These compounds may be administered either on their own or in conjunction with other active substances by intravenous, subcutaneous, intramuscular, intraperitoneal or intranasal route, by inhalation or transdermally or orally, whilst aerosol formulations are particularly suitable for inhalation.

For pharmaceutical use the compounds according to the invention are generally used for warm-blooded vertebrates, particularly humans, in doses of 0.01 -100 mg/kg of body weight, preferably 0.1-15 mg/kg. For administration they are formulated with one or more conventional inert carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, stearyl alcohol, ca rboxymethylcel I u lose or fatty substances such as hard fat or suitable mixtures thereof in conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions, solutions, sprays or suppositories.

Boehringer Ingelheim Pharma KG 39 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text The following Examples are intended to illustrate the present invention without restricting it:

Preparation of the starting compounds:
Example I

4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-benzyloxy-quinazoline-hydrochloride A mixture of 10.84 g 4-chloro-6-(tetrahydropyran-4-yloxy)-7-benzyloxy-quinazoline and 4.50 g 3-chloro-4-fluoranilin in 300 ml isopropanol is refluxed for four hours and then left to stand overnight at ambient temperature. The precipitate formed is suction filtered, washed with isopropanol and stirred with 150 ml of methanol. The suspension is stirred for another half hour at ambient temperature and then suction filtered. The filter cake is washed repeatedly with methanol and dried.
Yield: 9.07 g (60 % of theory) Rf value: 0.27 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI-): m/z = 478, 480 [M-H]-The following compounds are obtained analogously to Example I:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-benzyloxy-q uinazoline-hyd rochloride Rf value: 0.34 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 466, 468 [M+H]+

(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-trifluoroacetyl-piperidin-4-yloxy)-quinazoline-hydrochloride Rf value: 0.17 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 469, 471 [M+H]+

(3) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-trifluoroacetyl-piperidin-4-yloxy)-7-acetoxy-quinazoline-hydrochloride Rf value: 0.70 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 527, 529 [M+H]+

(4) 4-[(3-ethynyl-phenyl)amino]-6-acetoxy-7-methoxy-quinazoline Rf value: 0.59 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 334 [M+H]+
Example ii 4-chloro-6-(tetrahydropyran-4-yloxy)-7-benzyloxy-quinazoline Boehringer Ingelheim Pharma KG 41 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Prepared by reacting 6-(tetrahydropyran-4-yloxy)-7-benzyloxy-3H-quinazoline-4-on with thionyl chloride in the presence of N,N-dimethylformamide in acetonitrile at reflux temperature.
Rf value: 0.90 (silica gel, ethyl acetate/methanol = 9:1) The following compounds are obtained analogously to Example II:

(1) 4-chloro-6-((S)-tetrahydrofuran-3-yloxy)-7-benzyloxy-quinazoline Rf value: 0.85 (silica gel, ethyl acetate/methanol = 9:1) (2) 4-chloro-6-(1-trifluoroacetyl-piperidin-4-yloxy)-quinazoline Rf value: 0.92 (silica gel, ethyl acetate) (3) 4-chloro-6-(1-trifluoroacetyl-piperidin-4-yloxy)-7-acetoxy-quinazoline Example III

6-(tetrahyd ropyran-4-yloxy)-7-benzyloxy-3H-quinazoline-4-on A mixture of 15.08 g 2-amino-4-benzyloxy-5-(tetrahydropyran-4-yloxy)-benzoic acid and 14.40 g formamidine acetate in 250 ml of absolute ethanol is refluxed overnight. The cooled reaction mixture is combined with 250 ml of water. The precipitate formed is suction filtered and dried at 70 C in the drying cupboard.
Yield: 10.00 g (65 % of theory) Rf value: 0.40 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 353 [M+H]' The following compounds are obtained analogously to Example III:

(1) 6-((S)-tetrahydrofuran-3-yloxy)-7-benzyloxy-3H-quinazolin-4-one Rf value: 0.60 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Boehringer Ingelheim Pharma KG 42 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Mass spectrum (ESI+): m/z = 339 [M+H]+

(2) 6-[1 -(tert. -b utyloxycarbonyl)-p ipe rid in -4-yloxy]-3H-q u in azol i n-4-o ne Rf value: 0.48 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 346 [M+H]+

(3) 6-[1-(tert.-butyloxycarbonyl)-piperidin-4-yloxy]-7-hydroxy-3H-quinazolin-4-one Rf value: 0.35 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 362 [M+H]+

Example IV
2-amino-4-benzyloxy-5-(tetrahydropyran-4-yloxy)-benzoic acid 16.40 g 2-nitro-4-benzyloxy-5-(tetrahydropyran-4-yloxy)-benzoic acid are hydrogenated in the presence of 1.64 g Raney nickel in 800 ml of methanol at 55 C, until the calculated amount of hydrogen has been taken up. The catalyst is filtered off and the filtrate evaporated down, whereupon the desired product crystallises out.
Yield: 15.08 g (100 % of theory) Rf value: 0.60 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) The following compounds are obtained analogously to Example IV:

(1) benzyl 2-amino-4-benzyloxy-5-((S)-tetrahydrofuran-3-yloxy)-benzoate Rf value: 0.70 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 420 [M+H]+

(2) 2-amino-5-[1-(tert.-butyloxycarbonyl)-piperidin-4-yloxy]-benzoic acid Rf value: 0.43 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 337 [M+H]+

Boehringer Ingelheim Pharma KG 43 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (3) 2-amino-4-hydroxy-5-[1-(tert.-butyloxycarbonyl)-piperidin-4-yloxy]-benzoic acid Rf value: 0.23 (silica gel, methylene chloride/methanol/acetic acid = 90:10:1) Example V

2-nitro-4-benzyloxy-5-(tetrahydropyran-4-yloxy)-benzoic acid Prepared by saponification of benzyl 2-nitro-4-benzyloxy-5-(tetrahydropyran-4-yloxy)-benzoate with 1 N sodium hydroxide solution in methanol at ambient temperature.
Rf value: 0.20 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI{'): m/z = 374 [M+H]+
Example VI

Benzyl 2-nitro-4-benzyloxy-5-(tetrahydro-pyran-4-yloxy)-benzoate 42.60 g potassium-tert.-butoxide are added to 38 ml of tetrahydrofuran-4-ol in 228 ml N,N-dimethylformamide while cooling with an ice bath. The mixture is stirred for one hour at ambient temperature, then 22.90 g 6-nitro-benzo[1,3]dioxol-5-carboxylic acid are added. After 1.5 hours the reaction is complete according to thin layer chromatography and 28.94 ml of benzylbromide are added dropwise while cooling with an ice bath. The reaction mixture is stirred overnight at ambient temperature, combined with 100 ml 10% citric acid and stirred for another day at ambient temperature.
Then the reaction mixture is evaporated down in vacuo at 60 C and added to 800 ml ice water. The aqueous phase is extracted with ethyl acetate and the combined extracts are washed with water and saturated sodium chloride solution, dried over magnesium sulphate and evaporated.
The residue is stirred with diethyl ether, while 2-nitro-4-benzyloxy-5-(tetrahydropyran-4-yloxy)-benzoic acid crystallises out as a by-product. This is filtered off and the filtrate is evaporated down. The main product remaining is benzyl 2-nitro-4-benzyloxy-5-(tetrahydro-pyran-4-yloxy)-benzoate, which is Boehringer Ingelheim Pharma KG 44 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text saponified without any further purification to form carboxylic acid (see Example V).

The following compounds are obtained analogously to Example VI:

(1) benzyl 2-nitro-4-benzyloxy-5-((S)-tetrahydrofuran-3-yloxy)-benzoate Rf value: 0.75 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 450 [M+H]+

(2) 2-n itro-4-hyd roxy-5-[1 -(tert. -b utyloxyca rbonyl)-p i pe rid i n-4-yloxy]-be nzo ic acid No reaction is carried out with benzyl bromide.
Rf value: 0.40 (silica gel, methylene chloride/methanol/acetic acid = 90:10:1) Mass spectrum (ESI-): m/z = 381 [M-H]-Example VII
4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[2-(tert.-butyloxycarbonylamino)-ethyl]-piperidin-4-yloxy}-7-methoxy-quinazoline A mixture of 410 mg 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-4-yloxy)-7-methoxy-quinazoline-dihydrochloride, 240 mg N-(tert.-butyloxycarbonyl)-2-bromo-ethylamine and 360 mg potassium carbonate in 5 ml N,N-dimethylformamide is stirred overnight at ambient temperature. Then a further 80 mg of N-(tert.-butyloxycarbonyl)-2-bromo-ethylamine are added and the reaction mixture is stirred for a further four hours at ambient temperature.
For working up it is diluted with water and extracted with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over magnesium sulphate and evaporated. The residue is chromatographed through a silica gel column with ethyl acetate/methanol (95:5 to 90:1) as eluant.
Yield: 370 mg (79 % of theory) Rf value: 0.33 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Boehringer Ingelheim Pharma KG 45 Case 111317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Mass spectrum (ESI"): m/z = 544, 546 [M-H]-The following compound is obtained analogously to Example VII:
(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[2-(tert.-butyloxycarbonylamino)-ethyl]-piperidin-4-yloxy}-quinazoline Rf value: 0.38 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 516, 518 [M+H]+
Example VIII

4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-4-yloxy)-7-methoxy-quinazoline-dihydrochloride Prepared by treating 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(tert.-butyloxycarbonyl)-piperidin-4-yloxy]-7-methoxy-quinazoline with concentrated hydrochloric acid in dioxane at ambient temperature.
Rf value: 0.53 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 403, 405 [M+H]+

The following compounds are obtained analogously to Analog Example VIII:
(1) 6-(piperidin-4-yloxy)-3H-quinazolin-4-one x 2 trifluoroacetic acid Carried out with trifluoroacetic acid in methylene chloride.
Mass spectrum (ESI+): m/z = 246 [M+H]+

(2) 6-(piperidin-4-yloxy)-7-hydroxy-3H-quinazolin-4-one Carried out with trifluoroacetic acid in methylene chloride.
Rf value: 0.60 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 262 [M+H]+

Boehringer Ingelheim Pharma KG 46 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example IX

4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1 -(tert.-butyloxycarbonyl)-piperidin-4-yloxy]-7-methoxy-quinazoline A solution of 7.80 ml diethyl azodicarboxylate in 100 ml methylene chloride is added dropwise to a mixture of 10.00 g 4-[(3-chloro-4-fluoro-phenyl)amino]-6-hydroxy-7-methoxy-quinazoline and 9.40 g 1-(tert.-butyloxycarbonyl)-4-hydroxy-piperidine and 12.40 g triphenylphosphine in 400 ml methylene chloride at ambient temperature. The suspension is stirred for three days at ambient temperature and then suction filtered. The filtrate is evaporated and chromatographed through a silica gel column with methylene chloride/methanol (98:2 auf 95:5) as eluant. The crude product obtained is combined with diisopropylether, stirred overnight therein, suction filtered and dried.
Yield: 5.34 g (34 % of theory) Rf value: 0.46 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 503, 505 [M+H]+
Example X

4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahyd ropyran-4-yloxy)-7-(4-bromo-butyloxy)-quinazoline A mixture of 500 mg 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-hydroxy-quinazoline, 165 pl 1-bromo-4-chloro-propane and 360 mg potassium carbonate in 5 ml N,N-dimethylformamide is stirred overnight at 80 C. For working up the reaction mixture is diluted with water and extracted with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over magnesium sulphate and evaporated.
The crude product is further reacted without any more purification.
Yield: 650 mg (97 % of theory) The following compounds are obtained analogously to Example X:

Boehringer Ingelheim Pharma KG 47 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-(4-bromo-butyloxy)-quinazoline Rf value: 0.84 (silica gel, ethyl acetate/methanol = 9:1) (2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-trifluoroacetyl-piperidin-4-yloxy)-7-ethoxy-quinazoline Mass spectrum (ESI+): m/z = 513, 515 [M+H]+

(3) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-trifluoroacetyl-piperidin-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline Rf value: 0.38 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 543, 545 [M+H]+

Example Xl 1-(2-hydroxy-ethyl)-3-methyl-tetrahydropyrimidin-2-on Prepared by hydrogenolytically cleaving 1-(2-benzyloxy-ethyl)-3-methyl-tetrahydropy rimidin-2-one in the presence of palladium on activated charcoal in methanol at ambient temperature.
Rf value: 0.23 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 159 [M+H]+
Example XII

1-(2-benzyloxy-ethyl)-3-methyl-tetrahydropyrimidin-2-on Prepared by reacting 1-(2-benzyloxy-ethyl)-tetrahydropyrimidin-2-one with methyl iodide in the presence of potassium-tert.-butoxide in N,N-dimethylformamide at ambient temperature.
Rf value: 0.62 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): mlz = 249 [M+H]+

Boehringer Ingelheim Pharma KG 48 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example XIII

1 -(2-benzyloxy-ethyl)-tetrahyd ropyri mid in-2-on Prepared by treating 1-(2-benzyloxy-ethyl)-3-(3-chloro-propyl)-urea with potassium-tert.-butoxide in N,N-dimethylformamide at ambient temperature.
Rf value: 0.42 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 235 [M+H]+
Example XIV

1-(2-benzyloxy-ethyl)-tetrahydropyrimidin-2-one Prepared by reacting 2-benzyloxy-ethylamine with 3-chloro-propyl-isocyanate in tetrahydrofuran.
Rf value: 0.73 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 271, 273 [M+H]+
Example XV

3-(tert.-butyloxycarbonylamino)-cyclohexanol Prepared by reacting 3-amino-cyclohexanol with di-tert.butyl pyrocarbonate in the presence of triethylamine in a mixture of dioxan/water (2:1) at 50 C.
Rf value: 0.34 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI"): m/z = 214 [M-H]-The following compounds are obtained analogously to Example XV:
(1) cis-4-[N-(tert.-butyloxycarbonyl)-N-methyl-amino]-cyclohexanol The reaction takes place in methanol.
Rf value: 0.70 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 230 [M+H]+
IAdI I I UU A V I

6-(1-trifluoroacetyl-piperidin-4-yloxy)-3H-quinazolin-4-one Boehringer Ingeiheim Pharma KG 49 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example XVI

6-(1 -trifl u oroacetyl-p ipe rid i n-4-yloxy)-3H-q u in azol i n-4-one Prepared by reacting 6-(piperidin-4-yloxy)-3H-quinazolin-4-one x 2 trifluoroacetic acid with trifluoroacetic acid anhydride in the presence of triethylamine in tetrahydrofuran.
Rf value: 0.48 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 342 [M+H]+

The following compounds are obtained analogously to Example XVI:

(1) 6-(1-trifluoroacetyl-piperidin-4-yloxy)-7-hydroxy-3H-quinazolin-4-one Carried out with methyl trifluoroacetate in the presence of Honig base in methanol.
Rf value: 0.80 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum (ESI+): m/z = 358 [M+H]+

Example XVII
2-nitro-5-[1-(tert.-butyloxycarbonyl)-piperidin-4-yloxy]-benzoic acid 21.00 g potassium-tert.-butoxide are added batchwise to 25.14 g 1-(tert.-butyloxycarbonyl)-piperidin-4-oI in 120 ml N,N-dimethylformamide while cooling with an ice bath, while the temperature is kept below 10 C. The mixture is stirred for a further 30 minutes while cooling with an ice bath, then 11.60 g of 5-fluoro-2-nitro-benzoic acid are added. After another three hours the reaction mixture is poured onto water, adjusted to pH 1 with conc.
hydrochloric acid and extracted with ethyl acetate. The combined organic phases are washed with dilute citric acid solution, dried over magnesium sulphate and evaporated. The residue is triturated with diethyl ether, suction filtered and dried. More product crystallises out of the filtrate after standing for some time, and this is also suction filtered and dried.
Yield: 9.58 g (42 % of theory) Boehringer Ingelheim Pharma KG 50 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Rf value: 0.43 (silica gel, methylene chloride/methanol/acetic acid = 90:10:1) Mass spectrum (ESI+): m/z = 367[M+H]+

Example XVIII
4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-bromacetyl-piperidin-4-yloxy)-quinazoline and 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-chloracetyl-piperidin-4-yloxy)-quinazoline Prepared by reacting 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-4-yloxy)-quinazoline with bromoacetic acid chloride in the presence of Hunig base in tetrahydrofuran at ambient temperature. A mixture of the bromine and chlorine compounds is obtained.
Rf value: 0.43 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 493, 495, 497 [M1 +H]+ and 449, 451, 453 [M2+H]+

The following compounds are obtained analogously to Example XVIII:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-chloracetyl-piperidin-4-yloxy)-7-methoxy-quinazoline The reaction takes place with chloroacetyl chloride.
Rf value: 0.59 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI-): m/z = 477, 479, 481 [M-H]-Example XIX

1 -methyl-3-[([1,4]oxazepan-4-yl)carbonyl]-3H-imidazol-1 -ium-iodide Prepared by reacting 3-[([1,4]oxazepan-4-yl)carbonyl]-3H-imidazole with methyl iodide in acetonitrile at ambient temperature. The crude product is reacted further without any more purification.

The following compounds are obtained analogously to Example XIX:

(1) 1-methyl-3-[(cis-2,6-dimethyl-morpholin-4-yl)carbonyl]-3H-imidazol-1-ium-iodide Rf value: 0.12 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) (2) 1-methyl-3-[(2-methyl-morpholin-4-yl)carbonyl]-3H-imidazol-1-ium-iodide Rf value: 0.02 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Example XX
3-[([1,4]oxazepan-4-yl)carbonyl]-3H-imidazole Prepared by reacting [1,4]oxazepan with N,N'-carbonyldiimidazole in the presence of triethylamine in tetrahydrofuran at ambient temperature.
Rf value: 0.30 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 196 [M+H]+

The following compounds are obtained analogously to Example XX:
(1) 3-[(cis-2,6-dimethyl-morpholin-4-yl)carbonyl]-3H-imidazole Rf value: 0.46 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) (2) 3-[(2-methyl-morpholin-4-yl)carbonyl]-3H-imidazole Rf value: 0.43 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Example XXI
4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-trifluoroacetyl-piperidin-4-yloxy)-7-hydroxy-quinazoline Prepared by treating 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1 -trifluoroacetyl-p i perid in-4-yloxy)-7-acetoxy-q u in azol i ne-hyd roch lo ride with saturated sodium hydrogen carbonate solution in methanol at ambient temperature. In addition to the desired product, some 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-4-yloxy)-7-hydroxy-quinazoline is also isolated as a by-product.
Rf value: 0.20 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI'): m/z = 483, 485 [M-H]-The following compounds are obtained analogously to Example XXI:
(1) 4-[(3-ethynyl-phenyl)amino]-6-hydroxy-7-methoxy-quinazoline Carried out with 40 % sodium hydroxide solution in ethanol.
Rf value: 0.32 (silica gel, ethyl acetate) Mass spectrum (ESIi'): m/z = 292 [M+H]+
Example XXII

6-(1-trifl u oroacetyl-pi pe rid i n-4-yloxy)-7-acetoxy-3H-q u inazo li n-4-one Prepared by reacting 6-(1-trifluoroacetyl-piperidin-4-yloxy)-7-hydroxy-3H-quinazolin-4-one with acetic anhydride in pyridine at 80 C.
Rf value: 0.60 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 400 [M+H]+

Preparation of the end compounds:

Example 1 4-[(3-ch loro-4-fluoro-phenyl)amino]-6-((S)-tetrahyd rofuran-3-yloxy)-7-methoxy-quinazoline ci F

NH
N

kN O

300 mg of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-hydroxy-7-methoxy-quinazoline in 6 ml acetonitrile are combined with 114 pl (R)-3-hydroxy-tetrahydrofuran and 370 mg triphenyiphosphine. Then 234 pI diethyl azodicarboxylate are added and the reaction mixture is stirred overnight at ambient temperature. For working up the reaction mixture is filtered and the filtrate evaporated down in vacuo. The crude product is purified by chromatography over a silica gel column with ethyl acetate/methanol (95:5) as eluant.
Yield: 53 mg (15 % of theory) melting point: 178 C
Mass spectrum (ESI+): m/z = 390, 392 [M+H]+

The following compounds are obtained analogously to Example 1:

Boehringer Ingelheim Pharma KG 55 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-methoxy-quinazoline cl F

NH
N
O
N O I

Rf value: 0.54 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 404, 406 [M+H]+

(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(tert.-butyloxycarbonylamino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline cl F

NH
\ O
N

O NH

O O

Rf value: 0.70 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 517, 519 [M+H]+

(3) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((R)-tetrahydrofuran-3-yloxy)-7-methoxy-quinazoline Cl F

NH
N` O
O

Boehringer Ingelheim Pharma KG 56 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Rf value: 0.64 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 390, 392 [M+H]+

(4) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[trans-4-(tert.-butyloxycarbonylamino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline Cl F

NH
N

NH

Q 'It" 0 H3C>

Rf value: 0.65 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 517, 519 [M+H]+

(5) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(tert.-butyloxycarbonyl)-piperidin-4-yloxy]-7-methoxy-quinazoline cl F I:t~NH

N O
N O N ~O
I

melting point: 184 C
Mass spectrum (ESI+): m/z = 503, 505 [M+H]+

(6) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-3-yloxy)-7-methoxy-quinazoline Boehringer Ingelheim Pharma KG 57 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Cl F

NH
N \ xo Rf value: 0.52 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 404, 406 [M+H]+

(7) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline F
CI NH
I`
`N\OO NCH3 I

melting point: 218 C
Mass spectrum (ESI+): m/z = 417, 419 [M+H]+

(8) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(S)-1-(tert.-butyloxycarbonyl)-pyrrolidin-3-yloxy]-7-methoxy-quinazoline Carried out with diisopropyl azodicarboxylate in methylene chloride.
Rf value: 0.51 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 489, 491 [M+H]+

(9) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[ 1-(tert.-butyloxycarbonyl)-piperidin-3-yloxy]-7-methoxy-quinazoline Carried out with diisopropyl azodicarboxylate in methylene chloride.
Rf value: 0.56 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI"): m/z = 501, 503 [M-H]-Boehringer Ingelheim Pharma KG 58 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (10) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-[2-(3-methyl-2-oxo-hexahydropyrimidin-1-yl)-ethoxy]-quinazoline Carried out with diisopropyl azodicarboxylate in methylene chloride.
melting point: 235 C
Mass spectrum (ESI+): m/z = 516, 518 [M+H]+

(11) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[3-(tert.-butyloxycarbonylamino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline Carried out with diisopropyl azodicarboxylate in methylene chloride.
Rf value: 0.68 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI-): m/z = 515, 517 [M-H]"(12) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[N-(tert.-butyloxycarbonyl)-N-methyl-amino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline Carried out with diisopropyl azodicarboxylate in methylene chloride.
Rf value: 0.37 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 531, 533 [M+H]+

(13) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[N-(tert.-butyloxycarbonyl)-N-methyl-amino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline Carried out with diisopropyl azodicarboxylate in methylene chloride.
melting point: 231 C
Mass spectrum (ESI+): m/z = 531, 533 [M+H]+
Example 2 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-amino-cyclohexan-1 -yloxy)-7-methoxy-quinazoline x trifluoroacetic acid Boehringer Ingelheim Pharma KG 59 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text F /

Cl ~ NH
O
INII \ \
N O NHZ

Prepared by treating 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(tert.-butyloxycarbonylamino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline with trifluoroacetic acid in methylene chloride at ambient temperature.
melting point: 221 C
Mass spectrum (ESI+): m/z = 417, 419 [M+H]+

The following compounds are obtained analogously to Example 2:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-amino-cyclohexan-1-yloxy)-7-methoxy-quinazoline F /

CI \ NH
\
N O
kN / O NI-12 Mass spectrum (ESI+): m/z = 417, 419 [M+H]+

(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-4-yloxy)-7-methoxy-quinazoline x trifluoroacetic acid F /

CI NH
\ \

NH
N O

melting point: 232 C

Boehringer Ingelheim Pharma KG 60 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Mass spectrum (ESI+): m/z = 403, 405 [M+H]+

Example 3 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-methanesulphonylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline F

CI \ NH

N \ \ O O
I II
N O H Ise CH3 Prepared by reacting 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-amino-cyclohexan-l-yloxy)-7-methoxy-quinazoline x trifluoroacetic acid with methanesulphonic acid chloride in the presence of Hunig base in tetrahydrofuran at ambient temperature.
Rf value: 0.77 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
40:10:1) Mass spectrum (ESI+): mlz = 495, 497 [M+H]+

The following compounds are obtained analogously to Example 3:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methanesulphonylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline F

CI NH

N O O
N OI "N S(CH3 Rf value: 0.20 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 495, 497 [M+H]+

Boehringer Ingelheim Pharma KG 61 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline F /

CI \ NH

N O --ON
N O "S

Rf value: 0.59 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 481, 483 [M+H]+

(3) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(3-chloro-propyl)sulphonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline F /

CI NH

N \ O O
II
~N O NS
I H O

The reaction takes place with 3-chioropropansuiphonyl chloride.
Rf value: 0.79 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI"): m/z = 555, 557, 559 [M-H]-(4) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(3-chloro-propyl)sulphonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline F /

CI NH

IN \ \ O O
N O H ~~

Boehringer Ingelheim Pharma KG 62 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text The reaction takes place with 3-chloropropanesuiphonyl chloride.
Rf value: 0.42 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 557, 559, 561 [M+H]+

(5) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methylcarbonyl-piperidin-4-yloxy)-7-methoxy-quinazoline F
CI NH
N \ `\ O

O
N O NY
I

The reaction takes place with acetic anhydride.
melting point: 216 C
Mass spectrum (ESI+): m/z = 445, 447 [M+H]+

(6) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(dimethylamino)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline F

CI NH
N
O
kN ao I NY
CH3 H3C,N,~ CH3 The reaction takes place with N,N-dimethylcarbamoylchloride.
Rf value: 0.28 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 474, 476 [M+H]+

(7) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline Boehringer Ingelheim Pharma KG 63 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text F /

CI \ NH
N \ \ O
O N\ JO
1 `~
CH3 LIN) O
The reaction takes place with (morpholin-4-yl)carbonylchloride in acetonitrile.
Rf value: 0.37 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 516, 518 [M+H]+

(8) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(methoxymethyl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline F /

CI NH
o N
N O N O

The reaction takes place with methoxyacetic acid chloride.
Rf value: 0.80 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 475, 477 [M+H]+

(9) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline F /

CI NH
O
IIII
Dr' \
N O

Boehringer Ingelheim Pharma KG 64 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text The reaction takes place with bromocyanogen in methylene chloride.
Rf value: 0.40 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 428, 430 [M+H]+

(10) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(dimethylamino)sulphonyl]-piperid in-4-yloxy}-7-methoxy-quinazoline F
CI NH
O
N
NS~O
N O ~

CH3 H3C'~N,_ CH3 The reaction takes place with N,N-dimethylsulphamoylchloride in acetonitrile.
Rf value: 0.24 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 510, 512 [M+H]+

(11) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)sulphonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline F

CI \ NH

NIIII O
0-"ON O
N ~S

O
The reaction takes place with (morpholin-4-yl)sulphonyl chloride in acetonitrile.
Rf value: 0.29 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Boehringer Ingelheim Pharma KG 65 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Mass spectrum (ESI+): m/z = 552, 554 [M+H]+

(12) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-3-yloxy)-7-methoxy-quinazoline Rf value: 0.33 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 481, 483 [M+H]+

(13) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-1-methanesulphonyl-pyrrolidin-3-yloxy)-7-methoxy-quinazoline melting point: 249 C
Mass spectrum (ESI+): m/z = 467, 469 [M+H]+

(14) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-methanesulphonylamino-ethyl)-piperidin-4-yloxy]-7-methoxy-quinazoline Rf value: 0.49 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 524, 526 [M+H]+

(15) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-acetylamino-ethyl)-piperidin-4-yloxy]-7-methoxy-quinazoline The reaction takes place with acetic anhydride.
Rf value: 0.51 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 488, 490 [M+H]+

(16) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(dimethylamino)sulphonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline The reaction takes place with N,N-dimethylsulphamoylchloride in acetonitrile.
Rf value: 0.69 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 524, 526 [M+H]+

Boehringer Ingelheim Pharma KG 66 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (17) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline The reaction takes place with (morpholin-4-yl)carbonylchloride in acetonitrile.
Rf value: 0.38 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 530, 532 [M+H]+

(18) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(morpholin-4-yl)sulphonylamino]-cyclohexan-l-yloxy}-7-methoxy-quinazoline The reaction takes place with (morpholin-4-yl)sulphonyl chloride in acetonitrile.
melting point: 237 C
Mass spectrum (ESI-): m/z = 564, 566 (M-H]-(19) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(3-methanesulphonylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline Rf value: 0.66 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI-): m/z = 493, 495 (M-H]-(20) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-acetylamino-ethoxy)-quinazoline The reaction takes place with acetylchloride in acetonitrile.
melting point: 224 C
Mass spectrum (ESI+): m/z = 475, 477 [M+H]+

(21) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-methanesulphonylamino-ethoxy)-quinazoline melting point: 227 C
Mass spectrum (ESI+): m/z = 511, 513 [M+H]+

(22) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-3-acetylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline The reaction takes place with acetylchloride in acetonitrile. Cis- and trans-isomer are separated by chromatography over a silica gel column.
Rf value: 0.43 (silica gel, methylene chloride/methanol/conc. aqueous Boehringer Ingelheim Pharma KG 67 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 459, 461 [M+H]+
(23) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-3-acetylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline The reaction takes place with acetylchloride in acetonitrile. Cis- and trans-isomer are separated by chromatography over a silica gel column.
Rf value: 0.49 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 459, 461 [M+H]+
(24) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(3-acetylamino-propyloxy)-quinazoline The reaction takes place with acetylchloride.
melting point: 225 C
Mass spectrum (ESI+): m/z = 489, 491 [M+H]+
(25) 4-[(3-chloro-4-fl uoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(3-methanesulphonylamino-propyloxy)-quinazoline melting point: 222 C
Mass spectrum (ESI+): m/z = 525, 527 [M+H]+
(26) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-quinazoline Rf value: 0.44 (silica gel, methylene chloride /methanol = 9:1) Mass spectrum (ESI+): m/z = 451, 453 [M+H]+
(27) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-quinazoline The reaction takes place with (morpholin-4-yl)carbonylchloride in acetonitrile.
Rf value: 0.40 (silica gel, methylene chloride /methanol = 9:1) Mass spectrum (ESI+): m/z = 486, 488 [M+H]+
(28) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-acetyl-piperidin-4-yloxy)-Boehringer Ingelheim Pharma KG 68 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text quinazoline The reaction takes place with acetic anhydride.
Rf value: 0.50 (silica gel, methylene chloride /methanol = 9:1) Mass spectrum (ESI+): m/z = 415, 417 [M+H]+
(29) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(dimethylamino)carbonyl]-piperidin-4-yloxy}-quinazoline The reaction takes place with N,N-dimethylcarbamoylchloride.
Rf value: 0.47 (silica gel, methylene chloride /methanol = 9:1) Mass spectrum (ESI+): m/z = 444, 446 [M+H]+
(30) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-acetylamino-cyclohexan-1-yloxy}-7-methoxy-quinazoline The reaction takes place with acetic anhydride.
Rf value: 0.50 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 459, 461 [M+H]+
(31) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(dimethylamino)carbonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline The reaction takes place with N,N-dimethylcarbamoylchloride.
Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 488, 490 [M+H]+
(32) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[trans-4-(2-methoxy-acetylamino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline The reaction takes place with methoxyacetic acid chloride.
Rf value: 0.35 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 489, 491 [M+H]+
(33) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-methoxy-acetyl)-piperidin-4-yloxy]-quinazoline The reaction takes place with methoxyacetic acid chloride.
Rf value: 0.41 (silica gel, methylene chloride/methanol = 9:1) Boehringer Ingelheim Pharma KG 69 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Mass spectrum (ESI+): m/z = 445, 447 [M+H]+
(34) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-isopropyloxycarbonyl-piperidin-4-yloxy)-7-methoxy-quinazoline The reaction takes place with isopropyl chloroformate.
Rf value: 0.67 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
98:2:1) Mass spectrum (ESI+): m/z = 489, 491 [M+H]+
(35) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-quinazoline The reaction takes place with bromocyanogen in methylene chloride.
Rf value: 0.49 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI"): m/z = 396, 398 [M-H]-(36) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(dimethylamino)sulphonyl]-piperidin-4-yloxy}-quinazoline The reaction takes place with N,N-dimethylsulphamoylchloride in acetonitrile.
Rf value: 0.34 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 480, 482 [M+H]+
(37) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)sulphonyl]-piperidin-4-yloxy}-quinazoline The reaction takes place with (morpholin-4-yl)sulphonyl chloride in acetonitrile.
Rf value: 0.15 (silica gel, cyclohexane/ethyl acetate = 1:1) Mass spectrum (ESI+): m/z = 522, 524 [M+H]+
(38) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-acetylamino-ethyl)-piperidin-4-yloxy]-quinazoline The reaction takes place with acetic anhydride in acetonitrile.
melting point: 221 C
Mass spectrum (ESI+): m/z = 458, 460 [M+H]+

Boehringer Ingelheim Pharma KG 70 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (39) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(diethylamino)carbonyl]-piperid in-4-yloxy}-7-methoxy-quinazoline The reaction takes place with N,N-diethylcarbamoylchloride.
Rf value: 0.40 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
95:5:1) Mass spectrum (ESI+): m/z = 502, 504 [M+H]+
(40) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(piperidin-1-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline The reaction takes place with (piperidin-1-yl)carbonylchloride.
Rf value: 0.51 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
95:5:1) Mass spectrum (ESI-): m/z = 512, 514 [M-H]-(41) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(pyrrolidin-l-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline The reaction takes place with (pyrrolidin-1 -yl)carbonylchloride.
melting point: 237 C
Mass spectrum (ESI+): m/z = 500, 502 [M+H]+
(42) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(4-methyl-piperazin-1-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline The reaction takes place with (4-methyl-piperazin-1-yl)carbonylchloride-hydrochloride.
Rf value: 0.28 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI-): m/z = 527, 529 [M-H]-(43) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline The reaction takes place in methylene chloride.
Rf value: 0.71 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 509, 511 [M+H]+

Boehringer Ingelheim Pharma KG 71 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (44) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-acetyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline The reaction takes place with acetic anhydride.
melting point: 234 C
Mass spectrum (ESI+): m/z = 473, 475 [M+H]+
(45) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[N-(2-methoxy-acetyl)-N-methyl-amino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline The reaction takes place with methoxyacetic acid chloride.
Rf value: 0.40 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 503, 505 [M+H]+
(46) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-dimethylaminocarbonyl-N-methyl-amino)-cyclohexan-l-yloxy]-7-methoxy-quinazoline The reaction takes place with N,N-dimethylcarbamoylchloride.
Rf value: 0.51 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 502, 504 [M+H]+
(47) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline The reaction takes place with (morpholin-4-yl)carbonylchloride.
Rf value: 0.50 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 544, 546 [M+H]+
(48) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(morpholin-4-yl)sulphonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline The reaction takes place with (morpholin-4-yl)sulphonyl chloride in acetonitrile.
Rf value: 0.24 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 580, 582 [M+H]+

Boehringer Ingelheim Pharma KG 72 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (49) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-dimethylaminosulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline The reaction takes place with N,N-dimethylsulphamoylchloride in acetonitrile.
Rf value: 0.53 (silica gel, ethyl acetate) Mass spectrum (ESI+): m/z = 538, 540 [M+H]+
(50) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-ethanesulphonylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline The reaction takes place with ethanesulphonic acid chloride in methylene chloride.
Rf value: 0.41 (silica gel, ethyl acetate) Mass spectrum (ESI+): mlz = 509, 511 [M+H]+
(51) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-ethoxy-quinazoline The reaction takes place with (morpholin-4-yl)carbonylchloride.
Rf value: 0.48 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 530, 532 [M+H]+
(52) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-meth anesulphonyl-piperidin-4-yloxy)-7-ethoxy-quinazoline Rf value: 0.50 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 495, 497 [M+H]+
(53) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-methoxy-acetyl)-piperidin-4-yloxy]-7-ethoxy-quinazoline The reaction takes place with methoxyacetic acid chloride.
Rf value: 0.40 (silica gel, methylene chloride/methanol = 20:1) Mass spectrum (ESI+): m/z = 489, 491 [M+H]+
(54) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-meth anesulphonyl-piperidin-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline Rf value: 0.47 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 525, 527 [M+H]+

Boehringer Ingelheim Pharma KG 73 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (55) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidi n-4-yloxy}-7-(2-methoxy-ethoxy)-quinazoline The reaction takes place with (morpholin-4-yl)carbonylchloride.
Rf value: 0.48 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 560, 562 [M+H]+
(56) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-methoxy-acetyl)-piperidin-4-yloxy]-7-(2-methoxy-ethoxy)-quinazoline The reaction takes place with methoxyacetic acid chloride.
Rf value: 0.48 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 519, 521 [M+H]+
(57) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-acetylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline The reaction takes place with acetic anhydride.
melting point: 281 C
Mass spectrum (ESI+): m/z = 459, 461 [M+H]+
(58) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(2-methoxy-acetylamino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline The reaction takes place with methoxyacetic acid chloride.
melting point: 264 C
Mass spectrum (ESI+): m/z = 489, 491 [M+H]+
(59) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(piperidin-1-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline The reaction takes place with (piperidin-1-yl)carbonylchloride.
melting point: 253 C
Mass spectrum (ESI+): m/z = 542, 544 [M+H]+
(60) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(4-methyl-piperazin-1-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline Boehringer Ingelheim Pharma KG 74 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text The reaction takes place with (4-methyl-piperazin-1-yl)carbonylchloride-hydrochloride.
melting point: 262 C
Mass spectrum (ESI+): m/z = 557, 559 [M+H]+
(61) 4-[(3-chIoro-4-fluoro-phenyl)amino]-6-[cis-4-(N-ethanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline The reaction takes place with ethanesulphonic acid chloride in methylene chloride.
Rf value: 0.19 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 523, 525 [M+H]+
(62) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline The reaction takes place with (morpholin-4-yl)carbonylchloride.
Rf value: 0.33 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 530, 532 [M+H]+
(63) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(morpholin-4-yl)sulphonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline The reaction takes place with (morpholin-4-yl)sulphonyl chloride in acetonitrile.
Rf value: 0.81 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 566, 568 [M+H]+
(64) 4-[(3-ethynyl-phenyl)amino]-6-(1-acetyl-piperidin-4-yloxy)-7-methoxy-quinazoline The reaction takes place with acetic anhydride.
Rf value: 0.30 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 417 [M+H]+
(65) 4-[(3-ethynyl-phenyl)amino]-6-[1-(2-methoxy-acetyl)-piperidin-4-yloxy]-7-methoxy-quinazoline The reaction takes place with methoxyacetic acid chloride.
Rf value: 0.37 (silica gel, methylene chloride/methanoUconc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 447 [M+H]+
(66) 4-[(3-ethynyl-phenyl)amino]-6-(1-methanesulphonyl-pipe(din-4-yloxy)-7-methoxy-quinazoline Rf value: 0.59 (silica gel, ethyl acetate/methanoUconc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 453 [M+H]+
(67) 4-[(3-ethynyl-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy)-7-methoxy-quinazoline The reaction takes place with (morpholin-4-yl)carbonylchloride.
Rf value: 0.43 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 488 [M+H]+
(68) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[trans-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline Rf value: 0.50 (silica gel, methylene chloride /methanol = 9:1) Mass spectrum (ESI+): m/z = 509, 511 [M+H]+
(69) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline The reaction takes place with (morpholin-4-yl)carbonylchloride.
Rf value: 0.54 (silica gel, methylene chloride /methanol = 9:1) Mass spectrum (ESI+): m/z = 544, 546 [M+H]+

Example 4 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{[3-(morpholin-4-yl)-propyl]sulphonylamino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline F

CI \ NH

N O rO
N O N
I H O

23 pl of morpholine are added to 60 mg of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(3-chloro-propyl)sulphonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline in 2 ml acetonitrile and the reaction mixture is refluxed overnight. For working up the mixture is taken up in ethyl acetate and washed with water. The organic phase is dried over magnesium sulphate and evaporated down. The crude product is purified through a silica gel column with methylene chloride/methanol (9:1) as eluant.
Yield: 18 mg (27% of theory) Rf value: 0.36 (silica gel, methylene chloride /methanol = 9:1) Mass spectrum (ESI+): m/z = 608, 610 [M+H]+

The following compounds are obtained analogously to Example 4:

Boehringer Ingelheim Pharma KG 77 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-{[3-(morpholin-4-yl)-propyl]sulphonylamino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline F

Cl NH

O
li \ \ )O
N C H/ O N

Rf value: 0.16 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 608, 610 [M+H]+

(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-[4-(morpholin-4-yl)-butyloxy]-quinazoline Carried out in the presence of sodium carbonate and sodium iodide in N-methylpyrrolidone at 100 C.
Rf value: 0.18 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
40:10:0.5) Mass spectrum (ESI+): m/z = 531, 533 [M+H]+

(3) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-[4-(morpholin-4-yl)-butyloxy]-quinazoline Carried out in the presence of sodium carbonate and sodium iodide in N-methylpyrrolidone at 100 C.
Rf value: 0.32 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
80:20:1) Mass spectrum (ESI+): m/z = 517, 519 [M+H]+

(4) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)acetyl]-piperidin-4-yloxy}-quinazoline Carried out in the presence of Honig base in tetrahydrofuran at ambient temperature.

Boehringer Ingelheim Pharma KG 78 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Rf value: 0.30 (silica gel, methylene chloride /methanol = 9:1) Mass spectrum (ESI+): m/z = 500, 502 [M+H]+

(5) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-dimethylaminoacetyl-piperidin-4-yloxy)-quinazoline Carried out in the presence of Hunig base in tetrahydrofuran at ambient temperature.
Rf value: 0.11 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 458, 460 [M+H]+

(6) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-dimethyI aminoacetyl-piperidin-4-yloxy)-7-methoxy-quinazoline Carried out in the presence of Hunig base in tetrahydrofuran at ambient temperature.
Rf value: 0.19 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 488, 490 [M+H]+

(7) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)acetyl]-piperidin-4-yloxy}-7-methoxy-quinazoline Carried out in the presence of Hunig base in tetrahydrofuran at ambient temperature.
Mass spectrum (ESI+): m/z = 530, 532 [M+H]+
Example 5 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-pyrrolidin-3-yloxy)-7-methoxy-quinazoline-dihyd rochloride A solution of 370 mg 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(S)-1-(tert.-butyloxy-carbonyl)-pyrrolidin-3-yloxy]-7-methoxy-quinazoline in 5 ml dioxane is combined with 0.32 ml concentrated hydrochloric acid and stirred overnight at ambient temperature. The precipitate formed is suction filtered and washed Boehringer Ingelheim Pharma KG 79 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text with copious amounts of dioxane. The crude product is dissolved in a little methanol and re-precipitated by the addition of the same amount of ethyl acetate. The white solid thus obtained is suction filtered and dried.
Yield: 200 mg (57 % of theory) melting point: 281 C
Mass spectrum (ESI+): m/z = 389, 391 [M+H]+

The following compounds are obtained analogously to Example 5:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-3-yloxy)-7-methoxy-quinazoline-dihydrochloride melting point: 263 C
Mass spectrum (ESI+): m/z = 403, 505 [M+H]+

(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-amino-ethyl)-piperidin-4-yloxy]-7-methoxy-quinazoline-dihydrochloride melting point: 277 C
Mass spectrum (ESI+): m/z = 446, 448 [M+H]+

(3) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(3-amino-cyclohexan-1-yloxy)-7-methoxy-quinazoline-dihydrochloride Mass spectrum (ESI+): m/z = 417, 419 [M+H]+

(4) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-amino-ethoxy)-quinazoline-dihydrochloride Carried out with isopropanolic hydrochloric acid (5-6 M) in methylene chloride.
Rf value: 0.58 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 433, 435 [M+H]+

(5) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(3-amino-propyloxy)-quinazoline-dihydrochloride Carried out with isopropanolic hydrochloric acid (5-6 M) in methylene chloride.
Rf value: 0.44 (Reversed phase ready-made TLC plate (E. Merck), methanol/5% aqueous sodium chloride solution = 7:3) Mass spectrum (ESI+): m/z = 447, 449 [M+H]+

(6) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-amino-ethyl)-piperidin-4-yloxy]-quinazoline-dihydrochloride Rf value: 0.50 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 416, 418 [M+H]+

(7) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-methylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline-dihydrochloride Carried out with isopropanolic hydrochloric acid (5-6 M) in methylene chloride.
Rf value: 0.35 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 431, 433 [M+H]+

(8) 4-[(3-ethynyl-phenyl)amino]-6-(piperidin-4-yloxy)-7-methoxy-quinazoline-dihydrochloride Carried out with isopropanolic hydrochloric acid (5-6 M) in methylene chloride.
Rf value: 0.50 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 375 [M+H]+

(9) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline-dihydrochloride melting point: 251 C
Mass spectrum (ESI+): m/z = 431, 433 [M+H]+

Example 6 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-hydroxy-quinazoline A mixture of 9.00 g 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-benzyloxy-quinazoline-hydrochloride and 50 ml trifluoroacetic acid is heated to 100 C for 1.5 hours. Then the reaction mixture is evaporated and the residue is taken up in 10 ml acetonitrile. This solution is added dropwise to 100 ml saturated sodium hydrogen carbonate solution with vigorous stirring.
After 1.5 hours the precipitate formed is suction filtered and washed several times with water. The crude product is stirred with diethyl ether, suction filtered and dried.
Yield: 5.90 g (87 % of theory) Rf value: 0.21 (silica gel, ethyl acetate) Boehringer Ingelheim Pharma KG 82 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Mass spectrum (ESI+): m/z = 390, 392 [M+H]+

The following compounds are obtained analogously to Example 6:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-hydroxy-quinazoline Rf value: 0.44 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 376, 378 [M+H]+
Example 7 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-[3-(morpholin-4-yl)-propyloxy]-quinazoline A mixture of 300 mg 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-hydroxy-quinazoline, 130 mg 3-(morpholin-4-yl)-propylchloride and 530 mg potassium carbonate in 5 ml N,N-dimethylformamide is stirred overnight at 80 C. For working up the reaction mixture is diluted with 25 ml of water and extracted with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over magnesium sulphate and evaporated. The residue is stirred with diethyl ether, suction filtered and dried.
Yield: 250 mg (63 % of theory) melting point: 205 C
Mass spectrum (ESI+): m/z = 517, 519 [M+H]+

The following compounds are obtained analogously to Example 7:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-[2-(morpholin-4-yl)-ethoxy]-quinazoline Rf value: 0.33 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
40:10:0.5) Mass spectrum (ESI+): m/z = 503, 505 [M+H]+

Boehringer Ingelheim Pharma KG 83 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text (2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-ethoxy-quinazoline Rf value: 0.76 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 418, 420 [M+H]+

(3) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-[3-(morpholin-4-yl)-propyloxy]-quinazoline Rf value: 0.20 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI-): m/z = 501, 503[M-H]-(4) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-[2-(morpholin-4-yl)-ethoxy]-quinazoline Rf value: 0.19 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 489, 491 [M+H]+

(5) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline Rf value: 0.57 (silica gel, methylene chloride /methanol = 9:1) Mass spectrum (ESI+): m/z = 448, 450 [M+H]+

(6) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-[2-(tert.-butyloxycarbonylamino)-ethoxy]-quinazoline Rf value: 0.64 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
95:5:0.1) Mass spectrum (ESI+): m/z = 533, 535 [M+H]+

(7) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-[3-(tert.-butyloxycarbonylamino)-propyloxy]-quinazoline Rf value: 0.74 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
95:5:0.1) Mass spectrum (ESI+): m/z = 547, 549 [M+H]+

Boehringer Ingelheim Pharma KG 84 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example 8 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-4-yloxy)-quinazoline A solution of 4.55 g 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-trifluoroacetyl-piperidin-4-yloxy)-quinazoline-hydrochloride in 35 ml methanol is combined with 13 ml (3 N) sodium hydroxide solution and stirred for about half an hour at ambient temperature. For working up the reaction mixture is diluted with water and extracted with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over magnesium sulphate and evaporated. The residue is stirred with diethyl ether, suction filtered and dried.
Yield: 3.00 g (89 % of theory) Rf value: 0.48 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 373, 375 [M+H]+

The following compounds are obtained analogously to Example 8:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-4-yloxy)-7-ethoxy-quinazoline Rf value: 0.20 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 417, 419 [M+H]+

(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline Rf value: 0.10 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 447, 449 [M+H]+
Example 9 Boehringer Ingelheim Pharma KG 85 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(ethylamino)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline Prepared by reacting 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-4-yloxy)-7-methoxy-quinazoline with ethyl isocyanate in tetrahydrofuran at ambient temperature.
Rf value: 0.53 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 474, 476 [M+H]+

The following compounds are obtained analogously to Example 9:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(isopropylamino)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline melting point: 236 C
Mass spectrum (ESI"): m/z = 486, 488 [M-H]-(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(phenylamino)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline Rf value: 0.70 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
95:5:0.1) Mass spectrum (ESI+): m/z = 522, 524 [M+H]+

(3) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(ethylamino)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline Rf value: 0.38 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 502, 504 [M+H]+
Example 10 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(dimethylamino)carbonylmethyl]-piperidin-4-yloxy}-quinazoline Prepared by reacting 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-4-yloxy)-quinazoline with 2-chloro-N,N-dimethylacetamide in the presence of potassium carbonate in N,N-dimethylformamide at ambient temperature.
Rf value: 0.24 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 458, 460 [M+H]+

The following compounds are obtained analogously to Example 10:
(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonylmethyl]-piperid in-4-yloxy}-quinazoline Rf value: 0.42 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 500, 502 [M+H]+

(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-aminocarbonylmethyl-piperidin-4-yloxy)-7-methoxy-quinazoline melting point: 251 C
Mass spectrum (ESI+): m/z = 460, 462 [M+H]+
(3) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(dimethylamino)carbonylmethyl]-piperidin-4-yloxy}-7-methoxy-quinazoline melting point: 233 C
Mass spectrum (ESI+): m/z = 488, 490 [M+H]+

(4) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonylmethyl]-piperid in-4-yloxy}-7-methoxy-quinazoline melting point: 245 C
Mass spectrum (ESI+): m/z = 530, 532 [M+H]+

Example 11 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(tetrahydropyran-4-yl)carbonyl]-p i perid i n-4-yloxy}-7-methoxy-q u i n azo line 90 mg 1-hydroxy-1 H-benzotriazole and 250 mg 2-(1 H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate are added to a mixture of 300 mg 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-4-yloxy)-7-methoxy-quinazoline-dihydrochloride, 82 mg tetrahydropyran-4-carboxylic acid and 0.54 ml Honig base in 5 ml N,N-dimethylformamide. The reaction mixture is stirred overnight at ambient temperature. For working up it is combined with 25 ml ethyl acetate and washed with water, 10% potassium carbonate solution and saturated sodium chloride solution. The organic phase is dried over magnesium sulphate and evaporated. The residue is stirred with a little ethyl acetate, suction filtered and dried.
Yield: 250 mg (77 % of theory) Rf value: 0.43 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 515, 517 [M+H]' The following compounds are obtained analogously to Example 11:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(tetrahydropyran-4-yl)carbonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline Rf value: 0.44 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 529, 531 [M+H]+

(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(tetrahydropyran-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-l-yloxy)-7-methoxy-quinazoline Rf value: 0.31 (silica gel, ethyl acetate/methanol = 9:1) Mass spectrum (ESI+): m/z = 543, 545 [M+H]+
Example 12 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[([1,4]oxazepan-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-q u inazoline 4-[(3-ch loro-4-fluoro-phenyl)amino]-6-(piperid in-4-yloxy)-7-methoxy-quinazoline-dihydrochloride and 1.05 ml triethylamine are added to 900 mg of 1-methyl-3-[([1,4]oxazepan-4-yl)carbonyl]-3H-imidazol-1-ium-iodide in 10 ml methylene chloride. The yellowish suspension is stirred for about 24 hours at ambient temperature. For working up the reaction mixture is combined with 50 ml methylene chloride and extracted with water as well as 10% citric acid. The organic phase is washed with saturated sodium chloride solution, dried over magnesium sulphate and evaporated down. The residue is chromatographed through a silica gel column with methylene chloride/methanol/conc. ammonia as eluant. The desired product is stirred with diethyl ether, suction filtered and dried.
Yield: 800 mg (80 % of theory) Rf value: 0.30 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 530, 532 [M+H]+

The following compounds are obtained analogously to Example 12:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(cis-2,6-dimethyl-morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline Rf value: 0.41 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 544, 546 [M+H]+

(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(2-methyl-morpholin-4-yl)carbonyl]-piperid in-4-yloxy}-7-methoxy-quinazoline Rf value: 0.50 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) Mass spectrum (ESI+): m/z = 530, 532 [M+H]+

Boehringer Ingelheim Pharma KG 90 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Mass spectrum (ESI+): m/z = 532, 534 [M+H]+

Example 13 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-ethoxy-quinazoline 35 pl 37 % aqueous formalin solution and 110 mg of sodium triacetoxyborohydride are added to 175 mg 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-4-yloxy)-7-ethoxy-quinazoline in 1 ml of tetrahydrofuran. The reaction mixture is stirred for about four hours at ambient temperature. For working up 5 ml saturated sodium hydrogen carbonate solution are added and the mixture is stirred thoroughly. Then 20 ml ethyl acetate are added and the aqueous phase is separated off. The organic phase is washed with water and saturated sodium chloride solution, dried over magnesium sulphate and evaporated. The residue is stirred with diisopropylether, suction filtered and dried.
Yield: 144 mg (80 % of theory) Rf value: 0.80 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 60:10:1) Mass spectrum (ESI+): m/z = 431, 433 [M+H]+

The following compounds are obtained analogously to Example 13:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperid in-4-yloxy)-7(2-methoxy-ethoxy)-quinazoline Rf value: 0.85 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 60:10:1) Mass spectrum (ESI+): m/z = 461, 463 [M+H]+

(2) 4-[(3-ethynyl-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline-hydrochloride Rf value: 0.26 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 389 [M+H]+

(3) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-dimethylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline Rf value: 0.80 (aluminium oxide, methylene chloride/methanol = 9:1) Mass spectrum (ESI+): m/z = 445, 447 [M+H]+

Example 14 4-[(3-ethynyl-phenyl)amino]-6-[1-(tert.-butyloxycarbonyl)-piperidin-4-yloxy]-7-methoxy-quinazoline A mixture of 3.00 g 4-[(3-ethynyl-phenyl)amino]-6-hydroxy-7-methoxy-quinazoline, 4.50 g 1-(tert.-butyloxycarbonyl)-4-(p-toluolsulphonyloxy)-piperidin and 2.90 g potassium carbonate in 30 ml N,N-dimethylformamide is stirred for two days at 60 C. For working up the mixture is combined with 200 ml ethyl acetate and extracted with water. The organic phase is washed with saturated sodium chloride solution, dried over magnesium sulphate and evaporated. The crude product is purified over a silica gel column with methylene chloride/methanol/conc. ammonia as eluant.
Yield: 3.25 g (67 % of theory) Rf value: 0.25 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:1) Mass spectrum (ESI+): m/z = 475 [M+H]+

The following compounds are obtained analogously to Example 14:

(1) 4-[(3-ethynyl-phenyl)amino]-6-(tetrahydropyran-4-yloxy]-7-methoxy-quinazoline Rf value: 0.40 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 376 [M+H]+

Example 15 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[2-(tert.-butyloxycarbonylamino)-ethyl]-piperidin-4-yloxy}-7-methoxy-quinazoline A mixture of 410 mg of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-4-yloxy)-7-methoxy-quinazoline-dihydrochloride, 240 mg of N-(tert.-butyloxycarbonyl)-2-bromo-ethylamine and 360 mg of potassium carbonate in ml N,N-dimethylformamide is stirred overnight at ambient temperature. Then another 80 mg N-(tert.-butyloxycarbonyl)-2-bromo-ethylamine are added and the reaction mixture is stirred for a further four hours at ambient temperature.
For working up it is diluted with water and extracted with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over magnesium sulphate and evaporated. The residue is chromatographed through a silica gel column with ethyl acetate/methanol (95:5 to 90:1) as eluant.
Yield: 370 mg (79 % of theory) Rf value: 0.33 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI-): m/z = 544, 546 [M-H]-The following compound is obtained analogously to Example 15:
(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[2-(tert.-b utyloxycarbonylamino)-ethyl]-piperid in-4-yloxy}-q uinazoline Rf value: 0.38 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/ trifluoroacetic acid = 50:50:1) Mass spectrum (ESI+): m/z = 516, 518 [M+H]+

The following compounds may also be prepared analogously to the foregoing Examples and other methods known from the literature:

Boehringer Ingelheim Pharma KG 95 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure ( 1) F C) CI \ I N
O
I
O~UCY
(2) F
1\

\ \ O

O
CI \ I N
N L O

00, CI \ I N
N \ O
N

(5) F I `r ) CI \ 1 N
\ \ O
N
N OZO
CI \ I N Y
N \ \ O
~N O"~Nj-j (7) F 7 CI \ I N

\ a00""'N
N F

(8) CI \ I ~ C) N
N( \ \ O I^

Boehringer Ingelheim Pharma KG 96 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure CI I N
O
N ON"' (10) F C) CI aN
N L \ O
N O

(11) ` ~I C1 CI \ N

N~I L O
N ON~\/O\
O\
(12) F O~
CI \ N 9 O
N ~ O'er N
(13) I)\ N C) CI
O
N O------ON"
(14) J ~ IN `l' (' CI \' O

ON,-,, (15) )O C) CI ~ N
O
N( L

CI I N
(16) J
N
N O~\N ,N

Boehringer Ingeiheim Pharma KG 97 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (17) CI \ N

N O
N ON' `

(18) I ~ ~ 90 CI \ N N O~-N N

CI \ N
(19) F

N Oi\
O
(20) F aN

(21) F 1 0 CI \ I N
\ \ O

N II

CI a N
N
(22) I 7 O IN
N O-~-N~
(23) I
CI \ N
N
k'N\oO
"N6 (24) F C ) CI \ N

~N ~ ON

Boehringer Ingelheim Pharma KG 98 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure CI \ I N
(25) F /
N \ \ O

Q N / O^-~-N 00 (26) F /
CI \ I N
\
(N N O"`""'N
O
(27) CI \ N Y
i \ O

(28) F /
CI \ N
N \
/ \O
OQC/\
N

(29) F /
CI \ I N
O
N \ \
N 0 N~ N\/

(30) F /
N
CI~
Nl \ :X, ON If N~

(31) F /
CI \ I N
O
N \, \
N Nom/
(32) F /
CI \ N

N \ O` ^ O

Boehringer Ingelheim Pharma KG 99 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (33) F all CI N

N \ O` ~ O
(34) F
CI \ N
N
OO

(35) F /
CI \ N
\ p I
~ / Q Nom./'\~~\

(36) F /
CI \ N
N
O
O
N N
O
(37) F /
CI \ N

N O vNv N
(38) F /
CI \ N

N ON v 'N
I
(39) F /
CI \ N
N O` ^NJN/
7`vl (40) F /
CI \ N

N-,~~, I'll O"ONJ
o Boehringer Ingelheim Pharma KG 100 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (41) F /
CI \ N
~---/ O-ON 'N

(42) F /
CI \ I N

I=N
(43) F / i Cl \ N /\
NN O~`7 1N- Nlp I` ~ I /jj N
(44) F /
CI \ N
N

\/ I (45) F aN

CO
LN N
(46) F / I
CI \ N
\ O\^ O~-N /
N / n 7lvlN\/\~N
N

(47) F /
N
CI \ I
N \
N OQ N""N'tN
(48) F / I
Cl \ N R
N / 0 ON~"N N/
Li Boehringer Ingelheim Pharma KG 101 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (49) F / I
CI \ N

N'-!'!" c~o~\~N
V
(50) F /
CI \ N
N(I
N / n N~,~~N

(51) F /
CI \ N
`N O\ /\ N
(52) F /
CI \ I N

N O\ ^ N
~O
(53) F /
CI \ N
LO
N N N

(54) F /

CI \ N \J/~~' i / O\/ QQ
N~,,N, N \

(55) F / I
Cl \ N

' \ O` ^

(56) F /
CI \ I N

N ~.a NyN

Boehringer Ingelheim Pharma KG 102 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (57) F /
CI' 'N

II` / q N
Nõ \ O \/
N

(58) F /
CI \ I N

~lN
N O` ^ ~ N

(59) F /
CI \ N
\
~N Oq NN

(60) F /
CI \ N

N-,,; \ O` ^ N
qI
(61) F /
CI \ N

`ry QO(N
(62) F /
CI \ I N

lvlN
(63) F /

CI \ I N
ry~\ \ O~, gp N / N'illl\

(64) F /
CI \ I N

N OO---\N

Boehringer Ingelheim Pharma KG 103 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (65) F /
CI \ N

O v _N
(66) F
CI N

N N
(67) F /
CI/ v 'N
N
I

(68) F /
CI \ N
NN

(69) F /
CI \ N

N O~N~
1 ,N
(70) F /
CI \ N
O, O
N N" N
(71) F /
CI \ N
N O
\
i\ / N N
(72) F /
CI \ N
O
N \
kN / Q N'N

Boehringer Ingelheim Pharma KG 104 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (73) F
CI \ ! N

N N
(74) F !!
CI' O 'N
O
N \ \

N~ N" -N' (75) F

CI \ I N
O
\ \
N N" _ ~N~ N~
(76) F

CI \ ! N

N O^yN

(77) F
CI \ ! N
O
N NN, (78) F
CI \ ! N
O
N N-Y tt N~
OII
(79) F
CI \ I N
II`
N O ~`N 0 (80) F
CI \ ! N

N'~ N\/

Boehringer Ingelheim Pharma KG 105 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (81) F
CI N
N
(82) F
CI \ N

N / OON ~,N
I

(83) F \ I/
CI N

N N O-aN~' (84) F /
CI \ N

N O aN~ I.
(85) F /
CI \ N

~N / o-aN~/NJ
(86) F /
N
CI \

N \ O 0, /
N
(87) F /
CI \ N
NII \\O
N / N
I I
O
(88) F /
CI \ I N
\ \
N
I

Boehringer Ingelheim Pharma KG 106 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (89) F /
CI \ ( N
N
I
(90) F aN

C~(91) F /

CI \ N

II\ ^/
N, O V\N 0 N
(92) F /
CI \ N
INI \ O ON
~N,:T
D
(93) F /
CI \ I N

Nõ N O--aN------\N O
(94) F aN

CN \ \

N / OQ N---~-N" _N-(95) F /
CI \ N

N Q N""~ N
(96) F /
CI ~ N

ryIIl `N / N""N

Boehringer Ingelheim Pharma KG 107 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (97) 0 N)"
N O^~~ l (98) / \ I N
O
N 0"~ N0O
(99) Br \ N 9 N \ \
,N O""-"-"N

(100) ~ o CI \ I N Y

N N
(101) F \
CI \ I N 9 N O' '~

(102) I N O/ i N O

`N o'er`
O
(103) C ) N \ N ~J

N O~~N~

Boehringer Ingelheim Pharma KG 108 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (104) C
N N

N O"'N
O
(105) /I
N \ N
N

O
(106) )01N Y
C

NI \ \ O ^^
~N /

(107) F aN
CI N
(108) F
CI \ N
O
NIIII \ \

-ll (109) F n', CI N
O
o N

(110) F /
CI \ N
O
N\
(111) F /I
CI \ N
7I \

N Y
i Boehringer Ingelheim Pharma KG 109 Case 111317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (112) F a--l., CI' ~Or OyO
O
(113) F /
CI \ N

ON
N
-N
(114) F /

CI \ N

N 0"'a N N
(115) F aN

CO'CN
(116) F /
CI \ N
N~ i j 0.,, (117) F /
Cl \ N
N % O ^ O~
N O N/\i \)) (118) F /

CI \ N
NI O. O
N O aN -, (119) F /
CI \' N

~--~, O N/-NA

Boehringer Ingelheim Pharma KG 110 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (120) CI \ N

N a--- O"'aO
N O N"~'N 0 N
(121) F aN

CNN O
~N-N O

(122) F /

CI \ N
N - O
I
N O~
(123) F

CI N

NI \ \ N
~N / O
I

(124) F o CI \ N \
~,(N
N O N \~
N O
(125) F

CI \ N
II \ \ O
~N / oN CO
I

(126) F aN

CINI
`N O N

Boehringer Ingelheim Pharma KG 111 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (127) /
CI \ I N

kN oN~ O\

(128) F

CI \ N

N \ 0'-ON
N O O
IOI
(129) F'I
CI \ N

NI-\ xoo (130) F
CI \ N
O
N
N 0 NN~

(131) F n::, CI N
N~I \ \ O
`N~ / n NuN~~~O~
T O
(132) F

CI \ N

I
N\ 0 N 0 (133) F

CI \ N

N( O
Nu N, N O
O

Boehringer Ingelheim Pharma KG 112 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (134) F /

CI \ N

lI \ \
O
\ N N
N u /

(135) F aN

CINII \
O
`N -ON
(136) F /

CI \ N
O
N Ny O
(137) F aN

CIN O O
- / N N
N i T
O
(138) F / I
CI \ N

N, N / 0O-ON N!! O
(139) F /

CI \ N
Nl \
xoE
F'j, F

Boehringer Ingelheim Pharma KG 113 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (140) F / 1 CI \ N

O ro )ao N`~

(141) F

CI \ N

N \ 0 -N\ O ON V v N~
O
(142) F /

CI \ N

NlI \ ao Q~N=~/`\
(143) F

CI N

Gao I I
(144) F /

CI \ N
\ O

N / O N" O\
(145) F

CI \ N
NC'-,-N), O (146) F /

CI \ N
\ O

~N ON'-'-'N

Boehringer Ingelheim Pharma KG 114 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (147) F

CI

N - O Ou NN ON~/~NN/\
(148) F

CI \ N
O O
O N - ~N 0 N
(149) F

CI N
N O

kN / N~N 0 N
(150) F aN

CNN', N
(151) F /
CI \ N
O
N
~N O

(152) F /

CI \ N
N) NI ~/
O N~/N II

(153) F /

CI \ N
Nl \N /O ON,.,~N~ N~~

Boehringer Ingelheim Pharma KG 115 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (154) F

CI
N O

\N / O N/NuN
O
(156) F

CI \ N

l J
N,N O
\N / O
U
O
(157) F /

CI NH

NII ~ Na O-ON,,,~N
O
(158) F /

CI NH
O
INIII ~ O
NN
N' O
(159) F /

CI \ NH

N~ a O
O
N_,-,,_,N
N O O
(160) F /

CI \ N

NlI ~ \ o \N / ON , ~N /

Boehringer Ingelheim Pharma KG 116 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (161) / 1 F \ 0 CI// N

\ \
N

(162) F/~\ ~

CI N

xo (163) N /~\ I N
\ 0 e \ O
N / N
(164) ~

INI xo (165) / I
N CI \ NH

NIIII \ \
N / ON
(166) F / I
CI N
\ \
N / O
(167) F / I
CI \ NH 0 N \ \

Boehringer Ingelheim Pharma KG 117 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (168) F

~N / O v (169) F /

CI \ I N 0 NlI ao-O N `~N O O

(170) /
CI I \ I N
N
~N
,N N
O
(171) F

CI ~ N

NlI O
C-\N
N
O
(172) F /

CI \ N

N O rO
N
O
(173) F /

CI a N

N \ \ O
NyN
\N / 0,-,, Boehringer Ingelheim Pharma KG 118 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (174) F / I
Cl N

O
N O--"--N
O
(175) CI \ I N

II
O
(176) F /

CI \ N

N O
IN Y
O
(178) F /

CI N L O
0~/N
O
(179) F i l o CI \ N

NIIII " O
~N / Oil/N~Oi (180) F C
N O
CI \ N Y
IO
IN O~\/N
O

Boehringer Ingelheim Pharma KG 119 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example No. Structure (181) F I

CI

eN- \ O
O~/N OS~/\
I I
O
(182) /
CI \ I N

N \ ao,--,N O
'NUN
IO
(183) CI \ I N

Nl N / ~\/NuN\
IOI
(184) F / Cl ~ N

INI \ a N 0,--,,,N No y O
(185) F /

CI \ N
\
N O
,N / ^,,,Ny O
(186) F /

CI \ NH

N O
0,-,--,,N y Boehringer Ingelheim Pharma KG 120 Case 111317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example 16 Coated tablets containing 75 mg of active substance 1 tablet core contains:
active substance 75.0 mg calcium phosphate 93.0 mg corn starch 35.5 mg polyvinylpyrrolidone 10.0 mg hydroxypropylmethylcellulose 15.0 mg magnesium stearate 1.5 mq 230.0 mg Preparation:
The active substance is mixed with calcium phosphate, corn starch, polyvin-ylpyrrolidone, hydroxypropylmethylcellulose and half the specified amount of magnesium stearate. Blanks 13 mm in diameter are produced in a tablet-making machine and these are then rubbed through a screen with a mesh size of 1.5 mm using a suitable machine and mixed with the rest of the magnesium stearate. This granulate is compressed in a tablet-making machine to form tablets of the desired shape.
Weight of core: 230 mg die: 9 mm, convex The tablet cores thus produced are coated with a film consisting essentially of hydroxypropylmethylcellulose. The finished film-coated tablets are polished with beeswax.
Weight of coated tablet: 245 mg.

Boehringer Ingelheim Pharma KG 121 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example 17 Tablets containing 100 mg of active substance Composition:
1 tablet contains:
active substance 100.0 mg lactose 80.0 mg corn starch 34.0 mg polyvinylpyrrolidone 4.0 mg magnesium stearate 2.0 mg 220.0 mg Method of Preparation:

The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50 C it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets.
Weight of tablet: 220 mg Diameter: 10 mm, biplanar, facetted on both sides and notched on one side.

Example 18 Tablets containing 150 mg of active substance Composition:
1 tablet contains:
active substance 50.0 mg powdered lactose 89.0 mg corn starch 40.0 mg colloidal silica 10.0 mg polyvinylpyrrolidone 10.0 mg magnesium stearate 1.0 mg 300.0 mg Boehringer Ingeiheim Pharma KG 122 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Preparation:

The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45 C, are passed through the same screen again and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture.
Weight of tablet: 300 mg die: 10 mm, flat Example 19 Hard gelatine capsules containing 150 mg of active substance 1 capsule contains:
active substance 50.0 mg corn starch (dried) approx. 80.0 mg lactose (powdered) approx. 87.0 mg magnesium stearate 3.0 mg approx. 420.0 mg Preparation:

The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is packed into size 1 hard gelatine capsules.
Capsule filling: approx. 320 mg Capsule shell: size I hard gelatine capsule.

Boehringer Ingelheim Pharma KG 123 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Example 20 Suppositories containing 150 mg of active substance 1 suppository contains:
active substance 150.0 mg polyethyleneglycol 1500 550.0 mg polyethyleneglycol 6000 460.0 mg polyoxyethylene sorbitan monostearate 840.0 mg 2000.0 mg Preparation:

After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moulds.
Example 21 Suspension containing 50 mg of active substance 100 ml of suspension contain:
active substance 1.00 g carboxymethylcellulose-Na-salt 0.10 g methyl p-hydroxybenzoate 0.05 g propyl p-hydroxybenzoate 0.01 g glucose 10.00 g glycerol 5.00 g 70% sorbitol solution 20.00 g flavouring 0.30 g dist. water 100 ml Preparation:

Boehringer Ingelheim Pharma KG 124 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text The distilled water is heated to 70 C. The methyl and propyl p-hydroxybenzoates together with the glycerol and sodium salt of carboxymethylcelIulose are dissolved therein with stirring. The solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring. After the sugar, the sorbitol solution and the flavouring have been added and dissolved, the suspension is evacuated with stirring to eliminate air.
ml of suspension contain 50 mg of active substance.
Example 22 Ampoules containing 10 mg active substance Composition:
active substance 10.0 mg 0.01 N hydrochloric acid q.s.
double-distilled water 2.0 ml Preparation:

The active substance is dissolved in the necessary amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 2 ml ampoules.

Example 23 Ampoules containing 50 mg of active substance Composition:
active substance 50.0 mg 0.01 N hydrochloric acid q.s.
double-distilled water 10.0 ml Boehringer Ingelheim Pharma KG 125 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text Preparation:

The active substance is dissolved in the necessary amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 10 ml ampoules.

Example 24 Capsules for powder inhalation containing 5 mg of active substance 1 capsule contains:

active substance 5.0 mg lactose for inhalation 15.0 mg 20.0 mg Preparation:
The active substance is mixed with lactose for inhalation. The mixture is packed into capsules in a capsule-making machine (weight of the empty capsule approx. 50 mg).

weight of capsule: 70.0 mg size of capsule = 3 Example 25 Inhalable solution for hand-held nebulisers containing 2.5 mg active substance 1 spray contains:

active substance 2.500 mg benzalkonium chloride 0.001 mg 1 N hydrochloric acid q.s.

Boehringer Ingelheim Pharma KG 126 Case 1/1317-Ro D-55216 INGELHEIM CA 02476008 2004-08-11 Foreign filing text ethanol/water (50/50) 15.000 mg Preparation:
The active substance and benzalkonium chloride are dissolved in ethanol/water (50/50). The pH of the solution is adjusted with 1 N
hydrochloric acid. The resulting solution is filtered and transferred into suitable containers for use in hand-held nebulisers (cartridges).

Contents of the container: 4.5 g

Claims (39)

CLAIMS:
1. A bicyclic heterocyclic compound of general formula (I), wherein R a denotes a hydrogen atom, R b denotes a 3-ethynylphenyl, 3-bromophenyl, 3,4-difluorophenyl or 3-chloro-4-fluoro-phenyl group, or a 3-chloro-4-benzyloxy-phenyl, 3-chloro-4-[(3-fluoro-benzyl)oxy]-phenyl, 4-(pyridin-3-yloxy)-phenyl, 4-[(6-methyl-pyridin-3-yl)oxy]-phenyl, 3-methyl-4-(pyridin-3-yloxy)-phenyl, 3-methyl-4-[(6-methyl-pyridin-3-yl)oxy]-phenyl, 3-chloro-4-(pyridin-3-yloxy)-phenyl or 3-chloro-4-[(6-methyl-pyridin-3-yl)oxy]-phenyl group, R c denotes a cyclohexyl group which is substituted in the 3 position or in the 4 position by a group R4-N-R5, wherein R4 denotes a hydrogen atom, a methyl or ethyl group and R5 denotes a hydrogen atom, a methyl, aminocarbonylmethyl, methylaminocarbonylmethyl, dimethylaminocarbonylmethyl, pyrrolidin-1-ylcarbonylmethyl, piperidin-1-ylcarbonylmethyl, piperazin-1-ylcarbonylmethyl, 4-methylpiperazin-1-ylcarbonylmethyl, morpholin-4-ylcarbonylmethyl, 2-(morpholin-4-yl-carbonyl)ethyl or 3-(morpholin-4-yl-carbonyl)propyl group, an ethyl, propyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, 2-(butyloxycarbonylamino)-ethyl, 2-aminoethyl, 3-aminopropyl, 2-(acetylamino)ethyl, 3-(acetylamino)propyl, 2-(ethylcarbonylamino)ethyl, 3-(ethylcarbonylamino)propyl, 2-(propylcarbonylamino)ethyl, 3-(propylcarbonylamino)propyl, 2-(ethylaminocarbonylamino)ethyl, 3-(ethylaminocarbonylamino)propyl, 2-(dimethylaminocarbonylamino)ethyl, 3-(dimethylaminocarbonylamino)propyl, 2-(morpholin-4-ylcarbonylamino)ethyl, 3-(morpholin-4-ylcarbonylamino)propyl, 2-(methylsulphonyl)ethyl, 3-(methylsulphonyl)propyl, 2-(methylsulphonyl-amino)ethyl or a 3-(methylsulphonylamino)propyl group, a 2-(2-oxo-pyrrolidin-1-yl)ethyl, 2-(2-oxopiperidin-1-yl)ethyl, 2-(3-oxo-morpholin-4-yl)ethyl, 2-(2-oxo-imidazolidin-1-yl)ethyl, 2-(2-oxo-3-methyl-imidazolidin-1-yl)ethyl, 2-(2-oxo-hexahydropyrimidin-1-yl)ethyl or a 2-(2-oxo-3-methyl-hexahydropyrimidin-1-yl)ethyl group, a 3-(2-oxo-pyrrolidin-1-yl)propyl, 3-(2-oxopiperidin-1-yl)propyl, 3-(3-oxo-morpholin-4-yl)propyl, 3-(2-oxo-imidazolidin-1-yl)propyl, 3-(2-oxo-3-methyl-imidazolidin-1-yl)propyl, 3-(2-oxo-hexahydropyrimidin-1-yl)propyl or a 3-(2-oxo-3-methyl-hexahydropyrimidin-1-yl)propyl group, a methylsulphonyl, ethylsulphonyl, 3-chloropropylsulphonyl, 2-(morpholin-4-yl)-ethylsulphonyl or a 3-(morpholin-4-yl)-propylsulphonyl group, a propyloxycarbonyl or butyloxycarbonyl group, a formyl, acetyl, ethylcarbonyl, propylcarbonyl, methoxyacetyl, (2-methoxyethyl)carbonyl, (3-methoxypropyl)carbonyl, tetrahydrofuran-2-ylcarbonyl, tetrahydropyran-4-ylcarbonyl, aminoacetyl, methylaminoacetyl, dimethylaminoacetyl, morpholin-4-ylacetyl, [2-(morpholin-4-yl)ethyl]carbonyl, [3-(morpholin-4-yl)propyl]carbonyl or a methylsulphonylacetyl group, a cyano, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, ethylaminocarbonyl, diethylaminocarbonyl, propylaminocarbonyl, (2-methoxyethyl)aminocarbonyl, N-methyl-N-(2-methoxyethyl)-aminocarbonyl, (3-methoxypropyl)aminocarbonyl, N-methyl-N-(3-methoxypropyl)-aminocarbonyl, phenylaminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, 2-methylmorpholin-4-ylcarbonyl, 2,6-dimethylmorpholin-4-ylcarbonyl, homomorpholin-4-ylcarbonyl, 2-oxa-5-aza-bicyclo[2.2.1 ]hept-5-ylcarbonyl, 3-oxa-8-aza-bicyclo[3.2.1 ]oct-8-ylcarbonyl, 8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, aminosulphonyl, methylaminosulphonyl, dimethylaminosulphonyl or a morpholin-4-ylsulphonyl group, a cyclohexyl group which is substituted in the 3 position or in the 4 position by a group R6, wherein R6 denotes a 2-oxo-pyrrolidin-1-yl, 2-oxopiperidin-1-yl, 3-oxo-morpholin-4-yl, 2-oxo-imidazolidin-1-yl, 2-oxo-3-methyl-imidazolidin-1-yl, 2-oxo-hexahydropyrimidin-1-yl or a 2-oxo-3-methyl-hexahydropyrimidin-1-yl group, a pyrrolidin-3-yl group which is substituted in the 1 position by the group R5, wherein R5 is as hereinbefore defined, a piperidin-3-yl group which is substituted in the 1 position by the group R5, wherein R5 is as hereinbefore defined, a piperidin-4-yl group which is substituted in the 1 position by the group R5, wherein R5 is as hereinbefore defined, or a tetrahydrofuran-3-yl, tetrahydropyran-3-yl or tetrahydropyran-4-yl group, R d denotes a hydrogen atom, a methoxy, difluoromethoxy or ethyloxy group, an ethyloxy group which is substituted in the 2 position by a group R6 or R7, wherein R6 is as hereinbefore defined and R7 denotes a hydroxy, methoxy, ethoxy, amino, dimethylamino, diethylamino, bis-(2-methoxyethyl)-amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, homomorpholin-4-yl, 2-oxa-5-aza-bicyclo[2.2.1 ]hept-5-yl, 3-oxa-8-aza-bicyclo[3.2.1 ]oct-8-yl, 8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl, piperazin-1-yl, 4-methylpiperazin-1-yl or 4-ethylpiperazin-1-yl group, or an acetylamino, ethylcarbonylamino, propylcarbonylamino, butylcarbonylamino, methoxyacetylamino, butyloxycarbonylamino, ethylaminocarbonylamino, dimethylaminocarbonylamino, pyrrolidin-1-ylcarbonylamino, piperidin-1-ylcarbonylamino, morpholin-4-y1carbonylamino, methylsulphonylamino, ethylsulphonylamino or butylsulphonylamino group, a propyloxy group which is substituted in the 3 position by a group R6 or R7, wherein R6 and R7 are as hereinbefore defined, or a butyloxy group which is substituted in the 4 position by a group R6 or R7, wherein R6 and R7 are as hereinbefore defined, and X denotes a nitrogen atom, wherein, unless stated otherwise, the abovementioned alkyl groups are straight-chained or branched, or a tautomer thereof, a stereoisomer thereof, a mixture of stereoisomers thereof or a salt thereof.
2. A bicyclic heterocyclic compound according to claim 1, wherein R a denotes a hydrogen atom, R b denotes a 3-bromophenyl, 3,4-difluorophenyl, 3-chloro-4-fluoro-phenyl or a 3-ethynylphenyl group, or a 3-chloro-4-benzyloxy-phenyl, 3-chloro-4-[(3-fluorobenzyl)oxy]-phenyl, 4-(pyridin-3-yloxy)-phenyl, 4-[(6-methyl-pyridin-3-yl)oxy]-phenyl, 3-methyl-4-(pyridin-3-yloxy)-phenyl, 3-methyl-4-[(6-methyl-pyridin-3-yl)oxy]-phenyl, 3-chloro-4-(pyridin-3-yloxy)-phenyl or 3-chloro-4-[(6-methyl-pyridin-3-yl)oxy]-phenyl group, R c denotes a cyclohexyl group which is substituted in the 3 position by an amino, acetylamino, tert.-butyloxycarbonylamino or methylsulphonylamino group, a cyclohexyl group which is substituted in the 4 position by an amino, methylamino, ethylamino, dimethylamino, aminocarbonylmethylamino, methylaminocarbonylmethylamino, dimethylaminocarbonylmethylamino, morpholin-4-ylcarbonylmethylamino, [3-(morpholin-4-ylcarbonyl)propyl]amino, [2-(methylsulphonyl)ethyl]amino, [3-(methylsulphonyl)propyl]amino or [2-(methylsulphonylamino)ethyl]amino group, a cyclohexyl group which is substituted in the 4 position by a[2-(2-oxo-pyrrolidin-1-yl)ethyl]amino, [2-(2-oxopiperidin-1-yl)ethyl]amino, [2-(2-oxo-imidazolidin-1-yl)ethyl]amino, [2-(2-oxo-3-methyl-imidazolidin-1-yl)ethyl]amino, [2-(2-oxo-hexahydropyrimidin-1-yl)ethyl]amino or [2-(2-oxo-3-methyl-hexahydropyrimidin-1-yl)ethyl]amino group, a cyclohexyl group which is substituted in the 4 position by a[3-(2-oxo-pyrrolidin-1-yl)propyl]amino, [3-(2-oxopiperidin-1-yl)propyl]amino, [3-(2-oxo-imidazolidin-1-yl)propyl]amino, [3-(2-oxo-3-methyl-imidazolidin-1-yI)propyl]amino, [3-(2-oxo-hexahydropyrimidin-1-yl)propyl]amino or [3-(2-oxo-3-methyl-hexahydropyrimidin-1-yl)propyl]amino group, a cyclohexyl group which is substituted in the 4 position by an acetylamino, N-(acetyl)-methylamino, aminomethylcarbonylamino, methylaminomethylcarbonylamino, dimethylaminomethylcarbonylamino, morpholin-4-ylmethylcarbonylamino, methoxyacetylamino, N-(methoxyacetyl)-methylamino, tetrahydropyran-4-ylcarbonylamino, N-(tetrahydropyran-4-ylcarbonyl)-methylamino, tert.-butyloxycarbonylamino, N-(tert.-butyloxycarbonyl)-methylamino, aminocarbonylamino, methylaminocarbonylamino, N-(ethylaminocarbonyl)-methylamino, dimethylaminocarbonylamino, N-(dimethylaminocarbonyl)-methylamino, N-(piperidin-1-ylcarbonyl)-methylamino, morpholin-4-ylcarbonylamino, N-(morpholin-4-ylcarbonyl)-methylamino or N-(4-methylpiperazin-1-ylcarbonyl)-methylamino group, a cyclohexyl group which is substituted in the 4 position by a 2-oxo-pyrrolidin-1-yl, 2-oxopiperidin-1-yl, 3-oxo-morpholin-4-yl, 2-oxo-imidazolidin-1-yl, 2-oxo-3-methyl-imidazolidin-1-yl, 2-oxo-hexahydropyrimidin-1-yl or a 2-oxo-3-methyl-hexahydropyrimidin-1-yl group, a cyclohexyl group which is substituted in the 4 position by a methylsulphonylamino, N-(methylsulphonyl)-methylamino, ethylsulphonylamino, N-(ethylsulphonyl)-methylamino, dimethylaminosulphonylamino, N-(dimethylaminosulphonyl)-methylamino, morpholin-4-ylsulphonylamino, N-(morpholin-4-ylsulphonyl)-methylamino- 3-chloropropylsulphonylamino, [2-(morpholin-4-yl)-ethyl]sulphonylamino or [3-(morpholin-4-yl)-propyl]sulphonylamino- group, a pyrrolidin-3-yl group, a pyrrolidin-3-yl group which is substituted in the 1 position by a methyl, acetyl, methoxyacetyl, tert.-butyloxycarbonyl, morpholin-4-ylcarbonyl or methylsulphonyl group, a piperidin-3-yl group, a piperidin-3-yl group which is substituted in the 1 position by a methyl, acetyl, methoxyacetyl, tert.-butyloxycarbonyl, morpholin-4-ylcarbonyl or methylsulphonyl group, a piperidin-4-yl group which is substituted in the 1 position by a methyl, ethyl, propyl, isopropyl, 2-hydroxyethyl, 2-methoxyethyl, 3-methoxypropyl, 2-(methylsulphonyl)-ethyl, 3-(methylsulphonyl)-propyl, 2-(tert.-butyloxycarbonylamino)-ethyl, 2-aminoethyl, 2-(acetylamino)-ethyl, 2-(ethylcarbonylamino)-ethyl, 2-(propylcarbonylamino)-ethyl, 2-(ethylaminocarbonylamino)-ethyl, 2-(dimethylaminocarbonylamino)-ethyl, 2-(morpholin-4-ylcarbonylamino)-ethyl, 3-(acetylamino)-propyl, 3-(ethylcarbonylamino)-propyl, 3-(propylcarbonylamino)-propyl, 3-(ethylaminocarbonylamino)-propyl, 3-(dimethylaminocarbonylamino)-propyl, 3-(morpholin-4-ylcarbonylamino)-propyl, 2-(methylsulphonylamino)-ethyl, 3-(methylsulphonylamino)-propyl, (aminocarbonyl)methyl, (methylaminocarbonyl)methyl, (dimethylaminocarbonyl)methyl, (pyrrolidin-1-ylcarbonyl)methyl, (morpholin-4-ylcarbonyl)methyl, 2-(morpholin-4-ylcarbonyl)-ethyl or 3-(morpholin-4-ylcarbonyl)-propyl group, a piperidin-4-yl group which is substituted in the 1 position by a 2-(2-oxo-pyrrolidin-1-yl)-ethyl, 2-(2-oxopiperidin-1-yl)-ethyl, 2-(3-oxomorpholin-4-yl)-ethyl, 2-(2-oxo-imidazolidin-1-yl)-ethyl, 2-(2-oxo-3-methyl-imidazolidin-1-yl)-ethyl, 2-(2-oxo-hexahydropyrimidin-1-yl)-ethyl or 2-(2-oxo-3-methyl-hexahydropyrimidin-1-yl)-ethyl group, a piperidin-4-yl group which is substituted in the 1 position by a 3-(2-oxo-pyrrolidin-1-yl)-propyl, 3-(2-oxopiperidin-1-yl)-propyl, 3-(3-oxomorpholin-4-yl)-, propyl, 3-(2-oxo-imidazolidin-1-yl)-propyl, 3-(2-oxo-3-methyl-imidazolidin-1-yl)-propyl, 3-(2-oxo-hexahydropyrimidin-1-yl)-propyl or 3-(2-oxo-3-methyl-hexahydropyrimidin-1-yl)-propyl group, a piperidin-4-yl group which is substituted in the 1 position by a formyl, acetyl, methoxyacetyl, (2-methoxyethyl)carbonyl, (3-methoxypropyl)carbonyl, methylsulphonylacetyl, aminoacetyl, methylaminoacetyl, (dimethylamino)acetyl, (morpholin-4-yl)acetyl, [2-(morpholin-4-yl)-ethyl]carbonyl, [3-(morpholin-4-yl)-propyl]carbonyl, tetrahydrofuran-2-ylcarbonyl or tetrahydropyran-4-ylcarbonyl group, a piperidin-4-yl group which is substituted in the 1 position by a cyano, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, (2-methoxyethyl)aminocarbonyl, N-methyl-N-(2-methoxyethyl)-aminocarbonyl, (3-methoxypropyl)aminocarbonyl, N-methyl-N-(3-methoxypropyl)-aminocarbonyl, isopropylaminocarbonyl, phenylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, 2-methylmorpholin-4-ylcarbonyl, 2,6-dimethylmorpholin-4-ylcarbonyl, homomorpholin-4-ylcarbonyl, 2-oxa-5-aza-bicyclo[2.2.1 ]hept-5-ylcarbonyl, 3-oxa-8-aza-bicyclo[3.2.1 ]oct-8-ylcarbonyl, 8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, isopropyloxycarbonyl or tert.-butyloxycarbonyl group, a piperidin-4-yl group which is substituted in the 1 position by a methylsulphonyl, ethylsulphonyl, [2-(morpholin-4-yl)-ethyl]sulphonyl, [3-(morpholin-4-yl)-propyl]sulphonyl, aminosulphonyl, methylaminosulphonyl, dimethylaminosulphonyl or morpholin-4-ylsulphonyl group, or a tetrahydrofuran-3-yl, tetra hyd ropyra n-3-yl or tetrahydropyran-4-yl group, R d denotes a hydrogen atom, a methoxy, difluoromethoxy or ethyloxy group, a 2-(morpholin-4-yl)ethyloxy, 3-(morpholin-4-yl)propyloxy or 4-(morpholin-4-yI)butyloxy group, a 3-(dimethylamino)propyloxy, 3-(diethylamino)propyloxy, 3-[bis-(2-methoxyethyl)-amino]propyloxy, 3-(piperazin-1-yl)propyloxy, 3-(4-methylpiperazin-1-yl)propyloxy or 3-(4-ethylpiperazin-1-yl)propyloxy group, a 3-(homomorpholin-4-yl)-propyloxy, 3-(2-oxa-5-aza-bicyclo[2.2.1 ]hept-5-yl)-propyloxy, 3-(3-oxa-8-aza-bicyclo[3.2.1 ]oct-8-yl)-propyloxy or 3-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-propyloxy group, a 2-(2-oxo-pyrrolidin- 1 -yl)-ethyloxy, 2-(2-oxopiperidin-1-yl)-ethyloxy, 2-(3-oxomorpholin-4-yl)-ethyloxy, 2-(2-oxo-imidazolidin-1-yl)-ethyloxy, 2-(2-oxo-3-methyl-imidazolidin-1-yl)-ethyloxy, 2-(2-oxo-hexahydropyrimidin-1-yl)-ethyloxy;
or 2-(2-oxo-3-methyl-hexahydropyrimidin-1-yl)-ethyloxy group, a 3-(2-oxo-pyrrolidin-1-yl)-propyloxy, 3-(2-oxopiperidin-1-yl)-propyloxy, 3-(3-oxomorpholin-4-yl)-propyloxy, 3-(2-oxo-imidazolidin-1-yl)-propyloxy, 3-(2-oxo-3-methyl-imidazolidin-1-yl)-propyloxy, 3-(2-oxo-hexahydropyrimidin-1-yl)-propyloxy or 3-(2-oxo-3-methyl-hexahydropyrimidin-1-yl)-propyloxy group, a 2-(methoxy)-ethyloxy, 2-(tert.-butyloxycarbonylamino)-ethyloxy, 2-(amino)-ethyloxy, 2-(acetylamino)-ethyloxy, 2-(ethylcarbonylamino)-ethyloxy, 2-(propylcarbonylamino)-ethyloxy, 2-(isobutylcarbonylamino)-ethyloxy, 2-(methoxyacetylamino)-ethyloxy, 2-(ethylaminocarbonylamino)-ethyloxy, 2-(dimethylaminocarbonylamino)-ethyloxy, 2-(pyrrolidin-1-ylcarbonylamino)-ethyloxy, 2-(pipe rid i n- 1 -ylca rbonylam i no)-ethyloxy, 2-(morpholin-4-ylcarbonylamino)-ethyloxy, 2-(methylsulphonylamino)-ethyloxy group, 2-(ethylsulphonylamino)-ethyloxy or 2-(butylsulphonylamino)-ethyloxy group, or a 3-(tert.-butyloxycarbonylamino)-propyloxy, 3-(amino)-propyloxy, 3-(acetylamino)-propyloxy or 3-(methylsulphonylamino)-propyloxy group, and X denotes a nitrogen atom, or a tautomer thereof, a stereoisomer thereof, a mixture of stereoisomers thereof or a salt thereof.
3. A bicyclic heterocyclic compound according to claim 1, wherein R a denotes a hydrogen atom, R b denotes a 3-chloro-4-fluoro-phenyl group or a 3-ethynylphenyl group, R c denotes a cyclohexyl group which is substituted in the 3 position by an amino, acetylamino, tert.-butyloxycarbonylamino or methylsulphonylamino group, a cyclohexyl group which is substituted in the 4 position by an amino, methylamino, dimethylamino, acetylamino, N-(acetyl)-methylamino, methoxyacetylamino, N-(methoxyacetyl)-methylamino, tetrahydropyran-4-ylcarbonylamino, N-(tetrahydropyran-4-ylcarbonyl)-methylamino, tert.-butyloxycarbonylamino, N-(tert.-butyloxycarbonyl)-methylamino, N-(ethylaminocarbonyl)-methylamino, dimethylaminocarbonylamino, N-(dimethylaminocarbonyl)-methylamino, N-(piperidin-1-ylcarbonyl)-methylamino, morpholin-4-ylcarbonylamino, N-(morpholin-4-ylcarbonyl)-methylamino, N-(4-methylpiperazin-1-ylcarbonyl)-methylamino, methylsulphonylamino, N-(methylsulphonyl)-methylamino, ethylsulphonylamino, N-(ethylsulphonyl)-methylamino, dimethylaminosulphonylamino, N-(dimethylaminosulphonyl)-methylamino, morpholin-4-ylsulphonylamino, N-(morpholin-4-ylsulphonyl)-methylamino, 3-chloropropyisulphonylamino, or [3-(morpholin-4-yl)-propyl]sulphonylamino group, a pyrrolidin-3-yl group, a pyrrolidin-3-yl group which is substituted in the 1 position by a tert.-butyloxycarbonyl or methylsulphonyl group, a piperidin-3-yl group, a piperidin-3-yl group which is substituted in the 1 position by a tert.-butyloxycarbonyl or methylsulphonyl group, a piperidin-4-yl group, a piperidin-4-yl group which is substituted in the 1 position by a methyl, (aminocarbonyl)methyl, (dimethylaminocarbonyl)methyl, (morpholin-4-ylcarbonyl)methyl, 2-(tert.-butyloxycarbonylamino)ethyl, 2-aminoethyl, 2-(acetylamino)ethyl, 2-(methylsulphonylamino)ethyl, cyano, acetyl, methoxyacetyl, (dimethylamino)acetyl, (morpholin-4-yl)acetyl, tetrahydropyran-4-ylcarbonyl, ethylaminocarbonyl, isopropylaminocarbonyl, phenylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, 2-methylmorpholin-4-ylcarbonyl, 2,6-dimethylmorpholin-4-ylcarbonyl, homomorpholin-4-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, isopropyloxycarbonyl, tert.-butyloxycarbonyl, methylsulphonyl, dimethylaminosulphonyl or morpholin-4-ylsulphonyl group, or a tetrahydrofuran-3-yl, tetrahydropyran-3-yl or tetra hydropyran-4-yl group, R d denotes a hydrogen atom, a methoxy or ethyloxy group, a 2-(morpholin-4-yl)ethyloxy, 3-(morpholin-4-yl)propyloxy or 4-(morpholin-4-yI)butyloxy group, a 2-(3-methyl-2-oxo-hexahydropyrimidin-1-yl)-ethyloxy group, a 2-(methoxy)-ethyloxy, 2-(tert.-butyloxycarbonylamino)-ethyloxy, 2-amino-ethyloxy, 2-(acetylamino)-ethyloxy or 2-(methylsulphonylamino)-ethyloxy group or a 3-(tert.-butyloxycarbonylamino)-propyloxy, 3-amino-propyloxy, 3-(acetylamino)-propyloxy or 3-(methylsulphonylamino)-propyloxy group, and X denotes a nitrogen atom, or a tautomer thereof, a stereoisomer thereof, a mixture of stereoisomers thereof or a salt thereof.
4. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-methoxy-quinazoline, or a salt thereof.
5. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-methoxy-quinazoline, or a salt thereof.
6. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-((R)-tetrahydrofuran-3-yloxy)-7-methoxy-quinazoline, or a salt thereof.
7. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-amino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, or a salt thereof.
8. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methanesulphonylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, or a salt thereof.
9. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-4-yloxy)-7-methoxy-quinazoline, or a salt thereof.
10. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, or a salt thereof.
11. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{[3-(morpholin-4-yl)-propyl]sulphonylamino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline, or a salt thereof.
12. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-3-yloxy)-7-methoxy-quinazoline, or a salt thereof.
13. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-{[3-(morpholin-4-yl)-propyl]sulphonylamino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline, or a salt thereof.
14. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline, or a salt thereof.
15. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, or a salt thereof.
16. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(methoxymethyl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, or a salt thereof.
17. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline, or a salt thereof.
18. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)sulphonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, or a salt thereof.
19. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-acetylamino-ethyl)-piperidin-4-yloxy]-7-methoxy-quinazoline, or a salt thereof.
20. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(dimethylamino)sulphonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline, or a salt thereof.
21. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline, or a salt thereof.
22. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(morpholin-4-yl)sulphonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline, or a salt thereof.
23. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-acetylamino-ethoxy)-quinazoline, or a salt thereof.
24. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-methanesulphonylamino-ethoxy)-quinazoline, or a salt thereof.
25. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline, or a salt thereof.
26. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline, or a salt thereof.
27. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(morpholin-4-yl)sulfonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline, or a salt thereof.
28. A compound according to claim 1, wherein the compound is 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-acetyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, or a salt thereof.
29. A physiologically acceptable salt of a compound as defined in any one of claims 1 to 28 with an inorganic or organic acid or base.
30. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 28 or a physiologically acceptable salt as defined in claim 29 and one or more inert carriers or diluents.
31. Use of a compound as defined in any one of claims 1 to 28 or a physiologically acceptable salt as defined in claim 29 in preparation of a pharmaceutical composition for treating a benign or malignant tumour, for preventing or treating a disease of the airways and lungs or for treating a disease of the gastrointestinal tract, the bile duct and the gall bladder.
32. Use of a compound as defined in any one of claims 1 to 28 or a physiologically acceptable salt as defined in claim 29 for treating a benign or malignant tumour, for preventing or treating a disease of the airways and lungs or for treating a disease of the gastrointestinal tract, the bile duct and the gall bladder.
33. A compound as defined in any one of claims 1 to 28 or a physiologically acceptable salt as defined in claim 29 for treating a benign or malignant tumour, for preventing or treating a disease of the airways and lungs or for treating a disease of the gastrointestinal tract, the bile duct and the gall bladder.
34. A pharmaceutical composition according to claim 30 for treating a benign or malignant tumour, for preventing or treating a disease of the airways and lungs or for treating a disease of the gastrointestinal tract, the bile duct and the gall bladder.
35. A process for preparing a pharmaceutical composition as defined in claim 30, wherein a compound as defined in any one of claims 1 to 28 or a physiologically acceptable salt as defined in claim 29 is admixed with one or more inert carriers or diluents.
36. Use of a compound as defined in claim 26 or a salt thereof in the treatment of chronic bronchitis.
37. A compound as defined in claim 26 or a salt thereof for use in the treatment of chronic bronchitis.
38. A process for preparing a compound of general formula I as defined in claim 1, wherein a) a compound of general formula wherein R a, R b, R d and X are defined as in claim 1, is reacted with a compound of general formula Z1 - R c ,(III) wherein R c is defined as in claim 1 and Z1 denotes a leaving group, or b) in order to prepare a compound of general formula I wherein R d denotes one of the optionally substituted alkyloxy groups defined in claim 1, a compound of general formula wherein R a, R b, R c and X are defined as in claim 1, is reacted with a compound of general formula Z2 - R d' ,(V) wherein R d' denotes a C1-4-alkyl group, a methyl group substituted by 1 to 3 fluorine atoms, an ethyl group substituted by 1 to 5 fluorine atoms, a C2-4-alkyl group substituted by a group R6 or R7, wherein R6 and R7 are defined as in claim 1, a C1-4-alkyl group which is substituted by a pyrrolidinyl, piperidinyl or homopiperidinyl group substituted in the 1 position by the group R8, or a C1-4-alkyl group which is substituted by a morpholinyl group substituted in the 4 position by the group R8, wherein R8 in each case is defined as in claim 1, and Z2 denotes a leaving group, or c) in order to prepare a compound of general formula I wherein R d denotes one of the alkyloxy groups defined in claim 1, which is substituted by an optionally substituted amino, alkylamino or dialkylamino group or by an optionally substituted heterocyclic group bound via an iminonitrogen atom, a compound of general formula wherein R a, R b, R c and X are defined as in claim 1 and Z3 denotes a leaving group, is reacted with ammonia, a corresponding, optionally substituted alkylamine, dialkylamine or an imino compound or the appropriate salt or derivative thereof, or d) in order to prepare a compound of general formula I wherein R d denotes a hydroxy group, a protecting group is cleaved from a compound of general formula wherein R a, R b, R c and X are defined as in claim 1 and R d" denotes a group which can be converted into a hydroxy group, or e) in order to prepare a compound of general formula I wherein R c contains a -NH- group, a protecting group is cleaved from a compound of general formula wherein R a, R b, R d and X are defined as in claim 1 and R c' has the meaning given for R c in claim 1, with the proviso that R c contains a protected nitrogen atom, or f) in order to prepare a compound of general formula I wherein R c contains an alkyl group substituted by an optionally substituted amino, alkylamino or dialkyamino group or by an optionally substituted heterocyclic group bound via a nitrogen atom, a compound of general formula wherein R a, R b, R d and X are defined as in claim 1, Z3 denotes a leaving group and R c" has the meaning given for R c in claim 1, with the proviso that a hydrogen atom bound to an aliphatic carbon atom is replaced by the group Z3, is reacted with ammonia, a corresponding, optionally substituted alkylamine, dialkylamine or an imino compound or an appropriate salt or derivative thereof and if desired a compound of general formula I thus obtained which contains an amino, alkylamino or imino group is converted by acylation, cyanation or sulphonylation into a corresponding acyl, cyano or sulphonyl compound of general formula I and/or a compound of general formula I thus obtained which contains an amino, alkylamino or imino group is converted by alkylation or reductive alkylation into a corresponding alkyl compound of general formula I and/or a compound of general formula I thus obtained which contains a chloro-C1-4-alkylsulphonyl or a bromo-C1-4-alkylsulphonyl group is converted by reaction with an amine into a corresponding amino-C1-4-alkylsulphonyl compound and/or a compound of general formula I thus obtained which contains a tert.-butyloxycarbonylamino, N-alkyl-N-(tert.-butyloxycarbonyl)amino or a N-tert.-butyloxycarbonylimino group is converted by treatment with an acid into a corresponding amino, alkylamino or imino compound of general formula I, and/or if necessary any protecting group used in the reactions described above is cleaved again and/or if desired a compound of general formula I thus obtained is resolved into the stereoisomers thereof and/or a compound of general formula I thus obtained is converted into a salt thereof.
39. A process according to claim 38, wherein the salt of the compound of general formula I obtained is a physiologically acceptable salt.
CA2476008A 2002-03-30 2003-03-25 Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them Expired - Fee Related CA2476008C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10214412A DE10214412A1 (en) 2002-03-30 2002-03-30 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and process for their preparation
DE10214412.5 2002-03-30
DE10231711.9 2002-07-13
DE2002131711 DE10231711A1 (en) 2002-07-13 2002-07-13 New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors or respiratory or gastrointestinal diseases
PCT/EP2003/003062 WO2003082290A1 (en) 2002-03-30 2003-03-25 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
CA2476008A1 CA2476008A1 (en) 2003-10-09
CA2476008C true CA2476008C (en) 2011-12-13

Family

ID=28676040

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2476008A Expired - Fee Related CA2476008C (en) 2002-03-30 2003-03-25 Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them

Country Status (24)

Country Link
EP (1) EP1492536B1 (en)
JP (1) JP4776882B2 (en)
KR (1) KR101064530B1 (en)
CN (1) CN1642552B (en)
AR (1) AR039187A1 (en)
AT (1) ATE557008T1 (en)
AU (1) AU2003226705B2 (en)
BR (1) BR0308902A (en)
CA (1) CA2476008C (en)
EA (2) EA200701302A1 (en)
HK (1) HK1079095A1 (en)
HR (1) HRP20040898A2 (en)
IL (1) IL164167A0 (en)
ME (1) MEP47208A (en)
MX (1) MXPA04009536A (en)
MY (1) MY127771A (en)
NO (1) NO329271B1 (en)
NZ (1) NZ536114A (en)
PE (1) PE20040169A1 (en)
PL (1) PL371188A1 (en)
RS (1) RS85404A (en)
TW (2) TW201024269A (en)
UY (1) UY27737A1 (en)
WO (1) WO2003082290A1 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU90901A (en) 1999-06-21 2004-07-15 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7576074B2 (en) * 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
BRPI0410720A (en) * 2003-05-27 2006-06-20 Pfizer Prod Inc quinazolines and pyrido [3,4-d] pyrimidines as tyrosine kinase receptor inhibitors
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
DE10334226A1 (en) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
KR20060054388A (en) * 2003-07-29 2006-05-22 아스트라제네카 아베 Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
RU2378268C2 (en) * 2003-09-16 2010-01-10 Астразенека Аб Quinoline derivatives as tyrosine kinase inhibitors
JP2007505873A (en) * 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ Quinazoline derivatives as tyrosine kinase inhibitors
DE602004004811T2 (en) * 2003-09-19 2007-11-22 Astrazeneca Ab quinazoline derivatives
PL1667992T3 (en) * 2003-09-19 2007-05-31 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10345875A1 (en) * 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods of preparation
DE10350717A1 (en) * 2003-10-30 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
CA2549869C (en) 2003-12-18 2015-05-05 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
KR101158440B1 (en) 2003-12-18 2012-07-06 얀센 파마슈티카 엔.브이. 3-cyano-quinoline derivatives with antiproliferative activity
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
NI200700147A (en) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv QUINAZOLINE DERIVATIVES KINE INHIBITORS TARGETING MULTIP
WO2006064196A1 (en) 2004-12-14 2006-06-22 Astrazeneca Ab Pyrazolopyrimidine compounds as antitumor agents
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
BRPI0607358A2 (en) * 2005-02-04 2009-09-01 Boeringer Ingelheim Internat Gmbh use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis as well as
WO2006081741A1 (en) * 2005-02-05 2006-08-10 Piaoyang Sun Quinazoline compounds or their medical salts and preparation and medical usage thereof
CA2599210A1 (en) * 2005-02-26 2006-08-31 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
US20100234371A1 (en) * 2005-08-22 2010-09-16 Frank Himmelsbach Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
WO2007034144A1 (en) 2005-09-20 2007-03-29 Astrazeneca Ab 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
US8404697B2 (en) 2005-11-11 2013-03-26 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
AU2006326157A1 (en) * 2005-12-12 2007-06-21 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof
JP2009529511A (en) * 2006-03-09 2009-08-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, methods of use and production thereof
BRPI0714211B8 (en) 2006-07-13 2021-05-25 Janssen Pharmaceutica Nv mtki quinazoline derivatives, their use and pharmaceutical composition comprising them
US20080221132A1 (en) * 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
CA2662617C (en) * 2006-09-11 2014-11-18 Changgeng Qian Quinazoline based egfr inhibitors containing a zinc binding moiety
PT2068880E (en) 2006-09-18 2012-07-12 Boehringer Ingelheim Int Method for treating cancer harboring egfr mutations
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
EA200901041A1 (en) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх BICYCLIC HETEROCYCLES CONTAINING THESE COMPOUNDS MEDICINES, THEIR APPLICATION AND METHOD OF OBTAINING THEM
EP1956010A1 (en) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclical heterocycles, medicines containing these compounds, their application and method for their production
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
JP5536647B2 (en) 2007-07-27 2014-07-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pyrrolopyrimidine
AU2009211523B2 (en) * 2008-02-07 2014-03-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
MX2010012442A (en) * 2008-05-13 2011-10-11 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline.
JP2011530493A (en) * 2008-08-08 2011-12-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cyclohexyloxy-substituted heterocycles, medicaments containing these compounds, and methods for producing them
JP5611207B2 (en) * 2008-08-08 2014-10-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Stereoselective preparation of bicyclic heterocycles
CA2733153C (en) * 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
CN101659658B (en) * 2008-08-29 2014-04-02 北大方正集团有限公司 Quinoline substituted by cyan
CN101659657B (en) * 2008-08-29 2014-05-14 北大方正集团有限公司 Quinoline substituted by cyan and preparation method and applications thereof
WO2010026029A1 (en) * 2008-09-03 2010-03-11 Boehringer Ingelheim International Gmbh Use of quinazoline derivatives for the treatment of viral diseases
WO2011003853A2 (en) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
EP2484678B1 (en) 2009-09-28 2015-01-21 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors
JP2012526779A (en) * 2010-02-15 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 4-[(3-Chloro-4-fluoro-phenyl) amino] -6- (cis-4- {N-[(morph-1-olin-4-yl) carbonyl] -N-methyl-amino} -cyclohexane -1-yloxy) -7-methoxy-quinazoline salts and hydrates, their use as medicaments and their preparation
CN102452988B (en) * 2010-10-27 2016-01-27 中国科学院化学研究所 A kind of quinazoline derivant and preparation method thereof
AU2012213556A1 (en) * 2011-02-01 2013-08-22 Boehringer Ingelheim International Gmbh 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof
KR101317809B1 (en) 2011-06-07 2013-10-16 한미약품 주식회사 Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cell and non-metalic salt lubricant
JP6105631B2 (en) 2012-02-09 2017-03-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro [5.5] undecane
WO2013143057A1 (en) 2012-03-26 2013-10-03 中国科学院福建物质结构研究所 Quinazoline derivative and application thereof
JP2015524400A (en) 2012-07-19 2015-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Fumarate salt of 9- [4- (3-chloro-2-fluoro-phenylamino) -7-methoxy-quinazolin-6-yloxy] -1,4-diaza-spiro [5.5] undecan-5-one , Its use and preparation as drugs
KR20140096571A (en) 2013-01-28 2014-08-06 한미약품 주식회사 Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one
LT2964638T (en) * 2013-03-06 2017-12-27 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
TWI771327B (en) * 2016-10-05 2022-07-21 英商使命醫療公司 Novel compounds
US11365189B2 (en) 2019-04-25 2022-06-21 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of tyrosine kinase
WO2021090245A1 (en) 2019-11-06 2021-05-14 Yuhan Corporation Pyrrolidine and piperidine compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19911509A1 (en) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
DE10042059A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10042058A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
TWI331604B (en) 2010-10-11
KR101064530B1 (en) 2011-09-14
AU2003226705B2 (en) 2008-11-06
IL164167A0 (en) 2005-12-18
JP2005529090A (en) 2005-09-29
WO2003082290A1 (en) 2003-10-09
EA200701302A1 (en) 2007-12-28
EA200401191A1 (en) 2005-04-28
CN1642552A (en) 2005-07-20
TW200406211A (en) 2004-05-01
ATE557008T1 (en) 2012-05-15
EP1492536A1 (en) 2005-01-05
UY27737A1 (en) 2003-10-31
EP1492536B1 (en) 2012-05-09
CN1642552B (en) 2010-05-12
EA009300B1 (en) 2007-12-28
PL371188A1 (en) 2005-06-13
MXPA04009536A (en) 2005-01-25
NO20043997L (en) 2004-10-27
KR20040094898A (en) 2004-11-10
JP4776882B2 (en) 2011-09-21
AU2003226705A1 (en) 2003-10-13
BR0308902A (en) 2005-01-04
MEP47208A (en) 2011-02-10
NO329271B1 (en) 2010-09-20
TW201024269A (en) 2010-07-01
HK1079095A1 (en) 2006-03-31
HRP20040898A2 (en) 2005-10-31
RS85404A (en) 2007-02-05
CA2476008A1 (en) 2003-10-09
NZ536114A (en) 2007-11-30
MY127771A (en) 2006-12-29
PE20040169A1 (en) 2004-05-24
AR039187A1 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
CA2476008C (en) Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US6924285B2 (en) Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
AU772520B2 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
US7456189B2 (en) Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US6617329B2 (en) Aminoquinazolines and their use as medicaments
US20020082270A1 (en) Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
CA2417897C (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20060100223A1 (en) Quinazoline derivatives and pharmaceutical compositions containing them
US20110136806A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
CA2631813A1 (en) Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof
AU2004213129A1 (en) Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof
CA2417042A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10326186A1 (en) Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
CA2677336A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
EP2298305A1 (en) 4-(N-Phenylamino)-quinazolines/quinolines as inhibitors of tyrosine kinases
CA2361770A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CA2540501C (en) Quinoline derivatives and quinazoline derivatives, medicaments containing said compounds, use thereof, and method for the production thereof
JP2007507445A6 (en) Quinoline and quinazoline derivatives, drugs containing the same, use thereof and preparation method thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140325